Đoković, Jelena

Link to this page

Authority KeyName Variants
orcid::0000-0003-0936-4276
  • Đoković, Jelena (19)
Projects
NanoCellEmoCog - Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platform Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200161 (University of Belgrade, Faculty of Pharmacy)
Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200026 (University of Belgrade, Institute of Chemistry, Technology and Metallurgy - IChTM) Development of micro- and nanosystems as carriers for drugs with anti-inflammatory effect and methods for their characterization
Behavioral ?ffects following repeated administration of newly synthesized ligands selective for distinct subtypes of GABAA receptor benzodiazepine binding site: comparison with standard psychopharmacologic drugs CEEPUS project CIII-RS-1113-02-1819-M-118533 - Central European Knowledge Alliance for Teaching, Learning & Research in Pharmaceutical Technology (CEKA PharmTech).
Division of Chemistry through grant CHE-1625735 to JC. The APC was funded by the Ministry of Education, Science and Technological, Development, the Republic of Serbia NeuroDeRisk - Neurotoxicity De-Risking in Preclinical Drug Discovery
Electroconducting and redox-active polymers and oligomers: synthesis, structure, properties and applications Ministry of Education, Science and Technological Development, Republic of Serbia, Grant no. 451-03-68/2020-14/200126 (University of Belgrade, Faculty of Mining and Geology)
National Institutes of Health, USA through grants R01 NS076517 and R01 MH096463 and National Science Foundation NIH financial support (DA-043204, R01NS076517)
This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Author's Bibliography

The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73

Đoković, Jelena; Nikolić, Ines; Sharmin, Dishary; Cook, James M.; Savić, Miroslav; Borchard, Gerrit; Savić, Snežana

(International Society of Drug Delivery Sciences and Technology (APGI), 2024)

TY  - CONF
AU  - Đoković, Jelena
AU  - Nikolić, Ines
AU  - Sharmin, Dishary
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Borchard, Gerrit
AU  - Savić, Snežana
PY  - 2024
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5575
AB  - INTRODUCTION Temporal lobe epilepsy is characterized by seizures, but can also be associated with mental health problems for which there are no clear treatment regimens. A proprietary compound, GL-II-73 - (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide, a positive allosteric modulator of α5-containing γ-aminobutyric acid (GABA) receptors, has been shown to be effective in the treatment of these comorbidities [1]. ...
PB  - International Society of Drug Delivery Sciences and Technology (APGI)
PB  - International Association for Pharmaceutical Technology (APV)
PB  - Italian Society of Technology and Legislation (S.T.E.L.F)
C3  - 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria
T1  - The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5575
ER  - 
@conference{
author = "Đoković, Jelena and Nikolić, Ines and Sharmin, Dishary and Cook, James M. and Savić, Miroslav and Borchard, Gerrit and Savić, Snežana",
year = "2024",
abstract = "INTRODUCTION Temporal lobe epilepsy is characterized by seizures, but can also be associated with mental health problems for which there are no clear treatment regimens. A proprietary compound, GL-II-73 - (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxamide, a positive allosteric modulator of α5-containing γ-aminobutyric acid (GABA) receptors, has been shown to be effective in the treatment of these comorbidities [1]. ...",
publisher = "International Society of Drug Delivery Sciences and Technology (APGI), International Association for Pharmaceutical Technology (APV), Italian Society of Technology and Legislation (S.T.E.L.F)",
journal = "14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria",
title = "The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5575"
}
Đoković, J., Nikolić, I., Sharmin, D., Cook, J. M., Savić, M., Borchard, G.,& Savić, S.. (2024). The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73. in 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria
International Society of Drug Delivery Sciences and Technology (APGI)..
https://hdl.handle.net/21.15107/rcub_farfar_5575
Đoković J, Nikolić I, Sharmin D, Cook JM, Savić M, Borchard G, Savić S. The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73. in 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria. 2024;.
https://hdl.handle.net/21.15107/rcub_farfar_5575 .
Đoković, Jelena, Nikolić, Ines, Sharmin, Dishary, Cook, James M., Savić, Miroslav, Borchard, Gerrit, Savić, Snežana, "The impact of the aqueous phase on the physicochemical characteristics of nanoemulsions loaded with patent protected compound GL-II-73" in 14th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, 18 - 21 March 2024, Vienna, Austria (2024),
https://hdl.handle.net/21.15107/rcub_farfar_5575 .

Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73

Đoković, Jelena; Marković, Bojan; Sharmin, Dishary; Cook, James M.; Savić, Miroslav; Savić, Snežana

(Macedonian Pharmaceutical Association, 2023)

TY  - CONF
AU  - Đoković, Jelena
AU  - Marković, Bojan
AU  - Sharmin, Dishary
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5049
AB  - Introduction Nanopharmaceuticals offer a good method to avoid some of the difficulties that novel drug candidates confront. They can be tailored to adjust their water solubility, half-life, biodistribution, and govern the release of the integrated medication. Because of the excipients utilized, lipid nanocarriers (liposomes, nanoemulsions (NEs), nanoparticles) have been used to increase brain targeting (1,2). The investigated compound (GL-II-73) - (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is imidazobenzodiazepine (IBZD) ligand that acts as positive allosteric modulator on α-GABAA receptors and was shown to possess combined antidepressant and pro-cognitive effects, making it a promising candidate for further research (3). This work aims to investigate the physicochemical features of GL-II-73 to pick the best parenteral nanodelivery system for prospective research to assess its parameters. Мaterials and methods The saturation solubility of GL-II-73 was determined by adding it in excess to various oils (medium chain triglycerides, soybean, castor, and fish oil) to assess the oil solubility for the substance and select the optimal oil phase composition capable of incorporating the highest concentration of the GL-II-73. It was necessary to test the substance's solubility in buffers of various pH values to determine whether it has pH-dependent solubility. This investigation was carried out by incubating GL-II-73 and studied mediums on vortex for 24 hours and centrifuging to isolate supernatants from which the GL-II-73 concentration was evaluated using the LC-MS/MS method. The measurements were taken three times. In addition, after a 24-hour equilibration interval and determination of the GL-II-73 concentration, the log P value was obtained in an octanol/water system. Based on these findings, preliminary GL-II-73 (NE) was prepared using the high pressure homogenization method. In brief, the oil and aqueous phases were prepared separately and heated to 50 ˚C. They were then pre-mixed at the rotor stator homogenizer before being homogenized for 10 discontinuous cycles at 800 bar on the high pressure homogenizer. After diluting the sample in 1:500, v/v, ultra-purified water, the resulting formulations were characterized in terms of droplet size using the dynamic light scattering (DLS) technique on a Zetasizer Nano ZS90 (Malvern Instruments Ltd., Worcestershire, U.K.). On the same equipment, the NE's zeta potential (ZP) was measured. In addition, the pH and conductivity of the samples were examined. The ultrafiltration technique was used to evaluate the encapsulation efficacy (EE) by depositing 2 ml of the material in Amicon Ultra-4; NMWL 10 kDa filter units and centrifuging at 4500 rcf for 90 minutes. The EE was computed as %EE = ((A formulation A filtrate)/A formulation) 100, where A formulation represents the compound content in the formulation and A filtrate represents the filtrate, which was diluted in methanol and analyzed for Gl-II-73 content using the LC-MS/MS technique. During the one-month storage period, these conditions were monitored. Results and discussion Table 1 shows the solubility of GL-II-73 in the oils and buffers tested. The relatively good oil solubility, together with the log P value of 2.09, suggested that NEs could be promising carriers for GL-II-73. The highest oil solubility was detected in medium chain triglycerides, making them the oil phase of choice for future formulation development. Based on the solubility in 0.1 M HCl and phosphate buffer pH 7.4, it is possible to deduce that GL-II-73 has pH dependent solubility, with increased solubility observed as pH decreases, most likely due to the presence of ionizable functional groups and multiple H-bond acceptors. This suggested that the best EE would most likely be obtained by increasing the pH of the aqueous phase and keeping the chemical entrapped in the NE droplets. Solubility in organic solvents revealed that methanol is the best solvent for GL-II-73, as expected given its greater polarity index compared to isopropanol, which is why it was chosen for future characterization. Based on the solubility study, NE of the following composition was prepared: oil phase - medium chain tryglicerides (20%, w/w), soybean lecithin (2%, w/w), buthylhidroxytoluen (0.05%, w/w) and aqueous phase polysorbate 80 (2%, w/w), glycerol (2.25%, w/w), sodium oleate (0.03%, w/w), GL-II-73 (0.2%, w/w) and highly purified water to 100. The values of physicochemical parameters (Z-ave, PDI, ZP, pH, conductivity, drug content and encapsulation efficacy), measured both initially and after one month of storage, indicate suitability for parenteral administration. Conclusion Preliminary studies suggested that NEs are good prospective carriers for GL-II-73, but further research is needed for stability optimization.
PB  - Macedonian Pharmaceutical Association
PB  - Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
C3  - 14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N. Macedonia
T1  - Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5049
ER  - 
@conference{
author = "Đoković, Jelena and Marković, Bojan and Sharmin, Dishary and Cook, James M. and Savić, Miroslav and Savić, Snežana",
year = "2023",
abstract = "Introduction Nanopharmaceuticals offer a good method to avoid some of the difficulties that novel drug candidates confront. They can be tailored to adjust their water solubility, half-life, biodistribution, and govern the release of the integrated medication. Because of the excipients utilized, lipid nanocarriers (liposomes, nanoemulsions (NEs), nanoparticles) have been used to increase brain targeting (1,2). The investigated compound (GL-II-73) - (4R)-8-ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is imidazobenzodiazepine (IBZD) ligand that acts as positive allosteric modulator on α-GABAA receptors and was shown to possess combined antidepressant and pro-cognitive effects, making it a promising candidate for further research (3). This work aims to investigate the physicochemical features of GL-II-73 to pick the best parenteral nanodelivery system for prospective research to assess its parameters. Мaterials and methods The saturation solubility of GL-II-73 was determined by adding it in excess to various oils (medium chain triglycerides, soybean, castor, and fish oil) to assess the oil solubility for the substance and select the optimal oil phase composition capable of incorporating the highest concentration of the GL-II-73. It was necessary to test the substance's solubility in buffers of various pH values to determine whether it has pH-dependent solubility. This investigation was carried out by incubating GL-II-73 and studied mediums on vortex for 24 hours and centrifuging to isolate supernatants from which the GL-II-73 concentration was evaluated using the LC-MS/MS method. The measurements were taken three times. In addition, after a 24-hour equilibration interval and determination of the GL-II-73 concentration, the log P value was obtained in an octanol/water system. Based on these findings, preliminary GL-II-73 (NE) was prepared using the high pressure homogenization method. In brief, the oil and aqueous phases were prepared separately and heated to 50 ˚C. They were then pre-mixed at the rotor stator homogenizer before being homogenized for 10 discontinuous cycles at 800 bar on the high pressure homogenizer. After diluting the sample in 1:500, v/v, ultra-purified water, the resulting formulations were characterized in terms of droplet size using the dynamic light scattering (DLS) technique on a Zetasizer Nano ZS90 (Malvern Instruments Ltd., Worcestershire, U.K.). On the same equipment, the NE's zeta potential (ZP) was measured. In addition, the pH and conductivity of the samples were examined. The ultrafiltration technique was used to evaluate the encapsulation efficacy (EE) by depositing 2 ml of the material in Amicon Ultra-4; NMWL 10 kDa filter units and centrifuging at 4500 rcf for 90 minutes. The EE was computed as %EE = ((A formulation A filtrate)/A formulation) 100, where A formulation represents the compound content in the formulation and A filtrate represents the filtrate, which was diluted in methanol and analyzed for Gl-II-73 content using the LC-MS/MS technique. During the one-month storage period, these conditions were monitored. Results and discussion Table 1 shows the solubility of GL-II-73 in the oils and buffers tested. The relatively good oil solubility, together with the log P value of 2.09, suggested that NEs could be promising carriers for GL-II-73. The highest oil solubility was detected in medium chain triglycerides, making them the oil phase of choice for future formulation development. Based on the solubility in 0.1 M HCl and phosphate buffer pH 7.4, it is possible to deduce that GL-II-73 has pH dependent solubility, with increased solubility observed as pH decreases, most likely due to the presence of ionizable functional groups and multiple H-bond acceptors. This suggested that the best EE would most likely be obtained by increasing the pH of the aqueous phase and keeping the chemical entrapped in the NE droplets. Solubility in organic solvents revealed that methanol is the best solvent for GL-II-73, as expected given its greater polarity index compared to isopropanol, which is why it was chosen for future characterization. Based on the solubility study, NE of the following composition was prepared: oil phase - medium chain tryglicerides (20%, w/w), soybean lecithin (2%, w/w), buthylhidroxytoluen (0.05%, w/w) and aqueous phase polysorbate 80 (2%, w/w), glycerol (2.25%, w/w), sodium oleate (0.03%, w/w), GL-II-73 (0.2%, w/w) and highly purified water to 100. The values of physicochemical parameters (Z-ave, PDI, ZP, pH, conductivity, drug content and encapsulation efficacy), measured both initially and after one month of storage, indicate suitability for parenteral administration. Conclusion Preliminary studies suggested that NEs are good prospective carriers for GL-II-73, but further research is needed for stability optimization.",
publisher = "Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy",
journal = "14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N. Macedonia",
title = "Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5049"
}
Đoković, J., Marković, B., Sharmin, D., Cook, J. M., Savić, M.,& Savić, S.. (2023). Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73. in 14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N. Macedonia
Macedonian Pharmaceutical Association..
https://hdl.handle.net/21.15107/rcub_farfar_5049
Đoković J, Marković B, Sharmin D, Cook JM, Savić M, Savić S. Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73. in 14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N. Macedonia. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5049 .
Đoković, Jelena, Marković, Bojan, Sharmin, Dishary, Cook, James M., Savić, Miroslav, Savić, Snežana, "Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73" in 14th Central European Symposium on Pharmaceutical Technology, 28th - 30th September, Ohrid, N. Macedonia (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5049 .

High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances

Mitrović, Jelena; Divović-Matović, Branka; Knutson, Daniel E.; Petković, Miloš; Đorović, Đorđe; Ranđelović, Danijela V.; Dobričić, Vladimir; Đoković, Jelena; Lunter, Dominique J.; Cook, James M.; Savić, Miroslav; Savić, Snežana

(Elsevier B.V., 2023)

TY  - JOUR
AU  - Mitrović, Jelena
AU  - Divović-Matović, Branka
AU  - Knutson, Daniel E.
AU  - Petković, Miloš
AU  - Đorović, Đorđe
AU  - Ranđelović, Danijela V.
AU  - Dobričić, Vladimir
AU  - Đoković, Jelena
AU  - Lunter, Dominique J.
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4434
AB  - Preclinical development of deuterated pyrazoloquinolinone ligands, promising drug candidates for various neuropsychiatric disorders, was hindered by unusually low solubility in water and oils. DK-I-60-3 (7-methoxy-d3- 2-(4-methoxy-d3-phenyl)-2,5-dihydro-3Hpyrazolo[4,3-c]quinolin-3-one) is one of such pyrazoloquinolinones, and we recently reported about increased oral bioavailability of its nanocrystal formulation (NC). Lipid nano- particles (LNP) with a high concentration of lecithin, which enhances loading capacity of the lipid matrix, may give rise to further improvement. After preformulation studies by differential scanning calorimetry and polarized light microscopy, LNP were prepared by the hot high pressure homogenization, and characterized in terms of particle size, morphology, and encapsulation efficacy. The layered structure visible on atomic force micrographs was confirmed by nuclear magnetic resonance. Obtained formulations were desirably stable, with small particle size (<100 nm), and high encapsulation efficacy (>99 %). Lecithin was partially fluid and most probably located in the outer shell of the particle, together with DK-I-60-3. While the hydrophobic part of polysorbate 80 was completely immobilized, its hydrophilic part was free in the aqueous phase. In oral neuropharmacokinetic study in rats, an around 1.5-fold increase of area under the curve with LNP compared to NC was noticed both in brain and plasma. In bioavailability study, F value of LNP (34.7 ± 12.4 %) was 1.4-fold higher than of NC (24.5 ± 7.8 %); however, this difference did not reach statistical significance. Therefore, employment of LNP platform in preclinical formulation of DK-I-60-3 imparted an incremental improvement of its physicochemical as well as pharmacokinetic behavior.
PB  - Elsevier B.V.
T2  - International Journal of Pharmaceutics
T1  - High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances
VL  - 633
DO  - 10.1016/j.ijpharm.2023.122613
ER  - 
@article{
author = "Mitrović, Jelena and Divović-Matović, Branka and Knutson, Daniel E. and Petković, Miloš and Đorović, Đorđe and Ranđelović, Danijela V. and Dobričić, Vladimir and Đoković, Jelena and Lunter, Dominique J. and Cook, James M. and Savić, Miroslav and Savić, Snežana",
year = "2023",
abstract = "Preclinical development of deuterated pyrazoloquinolinone ligands, promising drug candidates for various neuropsychiatric disorders, was hindered by unusually low solubility in water and oils. DK-I-60-3 (7-methoxy-d3- 2-(4-methoxy-d3-phenyl)-2,5-dihydro-3Hpyrazolo[4,3-c]quinolin-3-one) is one of such pyrazoloquinolinones, and we recently reported about increased oral bioavailability of its nanocrystal formulation (NC). Lipid nano- particles (LNP) with a high concentration of lecithin, which enhances loading capacity of the lipid matrix, may give rise to further improvement. After preformulation studies by differential scanning calorimetry and polarized light microscopy, LNP were prepared by the hot high pressure homogenization, and characterized in terms of particle size, morphology, and encapsulation efficacy. The layered structure visible on atomic force micrographs was confirmed by nuclear magnetic resonance. Obtained formulations were desirably stable, with small particle size (<100 nm), and high encapsulation efficacy (>99 %). Lecithin was partially fluid and most probably located in the outer shell of the particle, together with DK-I-60-3. While the hydrophobic part of polysorbate 80 was completely immobilized, its hydrophilic part was free in the aqueous phase. In oral neuropharmacokinetic study in rats, an around 1.5-fold increase of area under the curve with LNP compared to NC was noticed both in brain and plasma. In bioavailability study, F value of LNP (34.7 ± 12.4 %) was 1.4-fold higher than of NC (24.5 ± 7.8 %); however, this difference did not reach statistical significance. Therefore, employment of LNP platform in preclinical formulation of DK-I-60-3 imparted an incremental improvement of its physicochemical as well as pharmacokinetic behavior.",
publisher = "Elsevier B.V.",
journal = "International Journal of Pharmaceutics",
title = "High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances",
volume = "633",
doi = "10.1016/j.ijpharm.2023.122613"
}
Mitrović, J., Divović-Matović, B., Knutson, D. E., Petković, M., Đorović, Đ., Ranđelović, D. V., Dobričić, V., Đoković, J., Lunter, D. J., Cook, J. M., Savić, M.,& Savić, S.. (2023). High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances. in International Journal of Pharmaceutics
Elsevier B.V.., 633.
https://doi.org/10.1016/j.ijpharm.2023.122613
Mitrović J, Divović-Matović B, Knutson DE, Petković M, Đorović Đ, Ranđelović DV, Dobričić V, Đoković J, Lunter DJ, Cook JM, Savić M, Savić S. High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances. in International Journal of Pharmaceutics. 2023;633.
doi:10.1016/j.ijpharm.2023.122613 .
Mitrović, Jelena, Divović-Matović, Branka, Knutson, Daniel E., Petković, Miloš, Đorović, Đorđe, Ranđelović, Danijela V., Dobričić, Vladimir, Đoković, Jelena, Lunter, Dominique J., Cook, James M., Savić, Miroslav, Savić, Snežana, "High amount of lecithin facilitates oral delivery of a poorly soluble pyrazoloquinolinone ligand formulated in lipid nanoparticles: Physicochemical, structural and pharmacokinetic performances" in International Journal of Pharmaceutics, 633 (2023),
https://doi.org/10.1016/j.ijpharm.2023.122613 . .
3
2

Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73

Đoković, Jelena; Marković, Bojan; Sharmin, Dishary; Cook, James M.; Savić, Miroslav; Savić, Snežana

(Macedonian Pharmaceutical Association, 2023)

TY  - CONF
AU  - Đoković, Jelena
AU  - Marković, Bojan
AU  - Sharmin, Dishary
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5050
AB  - Nanopharmaceuticals offer a good option to avoid
some of the difficulties that novel drug candidates
confront. They can be tailored to adjust their water
solubility, half-life, biodistribution, and govern the release
of the integrated medication. Because of the excipients
utilized, lipid nanocarriers (liposomes, nanoemulsions
(NEs), nanoparticles) have been used to increase brain
targeting (Bisso et al., 2020; Ilić et al., 2023).
The investigated compound (GL-II-73) - (4R)-8-
ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-
benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is
imidazobenzodiazepine (IBZD) ligand that acts as positive
allosteric modulator on α-GABAA receptors and was
shown to possess combined antidepressant and pro-
cognitive effects, making it a promising candidate for
further research (Prevot et al., 2019).
This work aims to investigate the physicochemical
features of GL-II-73 to pick the best parenteral
nanodelivery system for prospective research to assess its
parameters.
PB  - Macedonian Pharmaceutical Association
PB  - Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy
C3  - Macedonian Pharmaceutical Bulletin
T1  - Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73
VL  - 69
IS  - Suppl 1
SP  - 53
EP  - 54
DO  - 10.33320/maced.pharm.bull.2023.69.03.026
ER  - 
@conference{
author = "Đoković, Jelena and Marković, Bojan and Sharmin, Dishary and Cook, James M. and Savić, Miroslav and Savić, Snežana",
year = "2023",
abstract = "Nanopharmaceuticals offer a good option to avoid
some of the difficulties that novel drug candidates
confront. They can be tailored to adjust their water
solubility, half-life, biodistribution, and govern the release
of the integrated medication. Because of the excipients
utilized, lipid nanocarriers (liposomes, nanoemulsions
(NEs), nanoparticles) have been used to increase brain
targeting (Bisso et al., 2020; Ilić et al., 2023).
The investigated compound (GL-II-73) - (4R)-8-
ethynyl-6-(2-fluorophenyl)-N,N,4-trimethyl-4H-
benzo[f]imidazo[1,5-a] [1,4]diazepine-3-carboxamide is
imidazobenzodiazepine (IBZD) ligand that acts as positive
allosteric modulator on α-GABAA receptors and was
shown to possess combined antidepressant and pro-
cognitive effects, making it a promising candidate for
further research (Prevot et al., 2019).
This work aims to investigate the physicochemical
features of GL-II-73 to pick the best parenteral
nanodelivery system for prospective research to assess its
parameters.",
publisher = "Macedonian Pharmaceutical Association, Ss. Cyril and Methodius University in Skopje, Faculty of Pharmacy",
journal = "Macedonian Pharmaceutical Bulletin",
title = "Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73",
volume = "69",
number = "Suppl 1",
pages = "53-54",
doi = "10.33320/maced.pharm.bull.2023.69.03.026"
}
Đoković, J., Marković, B., Sharmin, D., Cook, J. M., Savić, M.,& Savić, S.. (2023). Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73. in Macedonian Pharmaceutical Bulletin
Macedonian Pharmaceutical Association., 69(Suppl 1), 53-54.
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.026
Đoković J, Marković B, Sharmin D, Cook JM, Savić M, Savić S. Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73. in Macedonian Pharmaceutical Bulletin. 2023;69(Suppl 1):53-54.
doi:10.33320/maced.pharm.bull.2023.69.03.026 .
Đoković, Jelena, Marković, Bojan, Sharmin, Dishary, Cook, James M., Savić, Miroslav, Savić, Snežana, "Preformulation and development of preliminary nanoemulsion carrier for patent protected compound GL-II-73" in Macedonian Pharmaceutical Bulletin, 69, no. Suppl 1 (2023):53-54,
https://doi.org/10.33320/maced.pharm.bull.2023.69.03.026 . .

Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application

Đoković, Jelena; Marković, Bojan; Sharmin, Dishary; Cook, James M.; Savić, Miroslav; Savić, Snežana

(International Association of Physical Chemists, 2023)

TY  - CONF
AU  - Đoković, Jelena
AU  - Marković, Bojan
AU  - Sharmin, Dishary
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4999
AB  - Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application
Jelena Đoković1, Bojan Marković2, Dishary Sharmin3, James M Cook3, Miroslav Savić4, Snežana Savić1
1University of pharmacy - Faculty of pharmacy, Department of pharmaceutical technology and cosmetology, 11221 Belgrade, Serbia
2University of pharmacy - Faculty of pharmacy, Department of pharmaceutical chemistry, 11221 Belgrade, Serbia
3Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA
4University of pharmacy - Faculty of pharmacy, Department of pharmacology, 11221 Belgrade, Serbia
The maximum amount of drug that can be incorporated into lipid nanoemulsions (NE) is usually judged by their solubility in the internal phase of the formulation. This can lead to various problems, such as precipitation of the drug after processing the formulation or, depending on the preparation technique used, the use of a large amount of the drug. To this end, it is useful to consider other drug loading methods, especially in the early stages of formulation development. In this study, we aimed to find the best way to achieve the highest loading of GL-II -73 in NEs for future parenteral applications for in vivo animal studies. This ligand acts as a positive allosteric modulator at α-GABAA receptors with combined antidepressant and cognition enhancing effects. NEs were prepared using the high pressure homogenization technique, a standard technique for parenteral NE preparation. The oil phase (medium-chain triglycerides, soy lecithin, and butylated hydroxytoluene) and the aqueous phase (glycerol, polysorbate 80, and 0.01 M phosphate buffer, pH 8) were separately heated to 50 ˚C and mixed until all components were dissolved. The aqueous phase was added to the oil phase and processed first on a rotor-stator homogenizer at 11000 rpm for 1 minute and then on a high-pressure homogenizer at 800 bar for 10 cycles. This resulted in a droplet size of 117.1 ± 1.5 nm, a PDI of 0.060 ± 0.008, a zeta potential of - 43.3 ± 1.3 mV, a pH of 7.89 ± 0.02, and a conductivity of 1061.67 ± 5.51 S/cm, indicating initial suitability for parenteral use. Using the empirical method for drug loading, we were able to dissolve GL-II -73 in the oil phase and achieve a drug concentration of 1.5 mg/ml in NE. For our experimental setup, this required the use of 120 mg of GL-II -73 per experiment. For the passive drug loading procedure, we incubated 1 ml of the placebo NE in the eppendorf tube (in duplicate) with the excess drug (approximately 10 mg per tube) for 72 h. The drug was then added to the eppendorf tube. The excess of the undissolved drug was removed after centrifugation. The drug content in the supernatant was 3.10 ± 0.25 mg/ml, indicating above-average loading of the drug and possibly suggesting localization of the drug in the droplet-stabilising layer, but this needs to be further demonstrated. This approach could contribute to more rational formulation development in the selection of formulation factors.
Acknowledgments
This research was funded by the Science Fund of the Republic of Serbia, GRANT No 7749108, Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platform - NanoCellEmоCog.
PB  - International Association of Physical Chemists
C3  - 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
T1  - Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4999
ER  - 
@conference{
author = "Đoković, Jelena and Marković, Bojan and Sharmin, Dishary and Cook, James M. and Savić, Miroslav and Savić, Snežana",
year = "2023",
abstract = "Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application
Jelena Đoković1, Bojan Marković2, Dishary Sharmin3, James M Cook3, Miroslav Savić4, Snežana Savić1
1University of pharmacy - Faculty of pharmacy, Department of pharmaceutical technology and cosmetology, 11221 Belgrade, Serbia
2University of pharmacy - Faculty of pharmacy, Department of pharmaceutical chemistry, 11221 Belgrade, Serbia
3Department of Chemistry and Biochemistry and the Milwaukee Institute for Drug Discovery, University of Wisconsin-Milwaukee, Milwaukee, WI, 53201, USA
4University of pharmacy - Faculty of pharmacy, Department of pharmacology, 11221 Belgrade, Serbia
The maximum amount of drug that can be incorporated into lipid nanoemulsions (NE) is usually judged by their solubility in the internal phase of the formulation. This can lead to various problems, such as precipitation of the drug after processing the formulation or, depending on the preparation technique used, the use of a large amount of the drug. To this end, it is useful to consider other drug loading methods, especially in the early stages of formulation development. In this study, we aimed to find the best way to achieve the highest loading of GL-II -73 in NEs for future parenteral applications for in vivo animal studies. This ligand acts as a positive allosteric modulator at α-GABAA receptors with combined antidepressant and cognition enhancing effects. NEs were prepared using the high pressure homogenization technique, a standard technique for parenteral NE preparation. The oil phase (medium-chain triglycerides, soy lecithin, and butylated hydroxytoluene) and the aqueous phase (glycerol, polysorbate 80, and 0.01 M phosphate buffer, pH 8) were separately heated to 50 ˚C and mixed until all components were dissolved. The aqueous phase was added to the oil phase and processed first on a rotor-stator homogenizer at 11000 rpm for 1 minute and then on a high-pressure homogenizer at 800 bar for 10 cycles. This resulted in a droplet size of 117.1 ± 1.5 nm, a PDI of 0.060 ± 0.008, a zeta potential of - 43.3 ± 1.3 mV, a pH of 7.89 ± 0.02, and a conductivity of 1061.67 ± 5.51 S/cm, indicating initial suitability for parenteral use. Using the empirical method for drug loading, we were able to dissolve GL-II -73 in the oil phase and achieve a drug concentration of 1.5 mg/ml in NE. For our experimental setup, this required the use of 120 mg of GL-II -73 per experiment. For the passive drug loading procedure, we incubated 1 ml of the placebo NE in the eppendorf tube (in duplicate) with the excess drug (approximately 10 mg per tube) for 72 h. The drug was then added to the eppendorf tube. The excess of the undissolved drug was removed after centrifugation. The drug content in the supernatant was 3.10 ± 0.25 mg/ml, indicating above-average loading of the drug and possibly suggesting localization of the drug in the droplet-stabilising layer, but this needs to be further demonstrated. This approach could contribute to more rational formulation development in the selection of formulation factors.
Acknowledgments
This research was funded by the Science Fund of the Republic of Serbia, GRANT No 7749108, Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platform - NanoCellEmоCog.",
publisher = "International Association of Physical Chemists",
journal = "10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6",
title = "Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4999"
}
Đoković, J., Marković, B., Sharmin, D., Cook, J. M., Savić, M.,& Savić, S.. (2023). Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6
International Association of Physical Chemists..
https://hdl.handle.net/21.15107/rcub_farfar_4999
Đoković J, Marković B, Sharmin D, Cook JM, Savić M, Savić S. Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application. in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4999 .
Đoković, Jelena, Marković, Bojan, Sharmin, Dishary, Cook, James M., Savić, Miroslav, Savić, Snežana, "Searching for the best way to incorporate the proprietary compound GL-II -73 into the nanoemulsion carrier for prospective parenteral application" in 10th IAPC Meeting Tenth World Conference on Physico-Chemical Methods in Drug Discovery & Sixth World Conference on ADMET and DMPK Belgrade, Serbia, September 4-6 (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4999 .

Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation

Ilić, Tanja; Đoković, Jelena; Nikolić, Ines; Mitrović, Jelena; Pantelić, Ivana; Savić, Snežana; Savić, Miroslav

(MDPI, 2023)

TY  - JOUR
AU  - Ilić, Tanja
AU  - Đoković, Jelena
AU  - Nikolić, Ines
AU  - Mitrović, Jelena
AU  - Pantelić, Ivana
AU  - Savić, Snežana
AU  - Savić, Miroslav
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4515
AB  - Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery across the blood–brain barrier (BBB). The growing availability of innovative excipients/ligands allowing improved brain targeting and controlled drug release makes the lipid nanocarriers a reasonable choice to overcome the factors impeding drug delivery through the BBB. However, a wide variety of methods, study designs and experimental conditions utilized in the literature hinder their systematic comparison, and thus slows the advances in brain-targeting by lipid-based nanoparticles. This review provides an overview of the methods most commonly utilized during the preclinical testing of liposomes, nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers intended for the treatment of various CNS disorders via the parenteral route. In order to fully elucidate the structure, stability, safety profiles, biodistribution, metabolism, pharmacokinetics and immunological effects of such lipid-based nanoparticles, a transdisciplinary approach to preclinical characterization is mandatory, covering a comprehensive set of physical, chemical, in vitro and in vivo biological testing.
PB  - MDPI
T2  - Pharmaceutics
T1  - Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation
VL  - 15
IS  - 2
DO  - 10.3390/pharmaceutics15020443
ER  - 
@article{
author = "Ilić, Tanja and Đoković, Jelena and Nikolić, Ines and Mitrović, Jelena and Pantelić, Ivana and Savić, Snežana and Savić, Miroslav",
year = "2023",
abstract = "Contemporary trends in combinatorial chemistry and the design of pharmaceuticals targeting brain disorders have favored the development of drug candidates with increased lipophilicity and poorer water solubility, with the expected improvement in delivery across the blood–brain barrier (BBB). The growing availability of innovative excipients/ligands allowing improved brain targeting and controlled drug release makes the lipid nanocarriers a reasonable choice to overcome the factors impeding drug delivery through the BBB. However, a wide variety of methods, study designs and experimental conditions utilized in the literature hinder their systematic comparison, and thus slows the advances in brain-targeting by lipid-based nanoparticles. This review provides an overview of the methods most commonly utilized during the preclinical testing of liposomes, nanoemulsions, solid lipid nanoparticles and nanostructured lipid carriers intended for the treatment of various CNS disorders via the parenteral route. In order to fully elucidate the structure, stability, safety profiles, biodistribution, metabolism, pharmacokinetics and immunological effects of such lipid-based nanoparticles, a transdisciplinary approach to preclinical characterization is mandatory, covering a comprehensive set of physical, chemical, in vitro and in vivo biological testing.",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation",
volume = "15",
number = "2",
doi = "10.3390/pharmaceutics15020443"
}
Ilić, T., Đoković, J., Nikolić, I., Mitrović, J., Pantelić, I., Savić, S.,& Savić, M.. (2023). Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation. in Pharmaceutics
MDPI., 15(2).
https://doi.org/10.3390/pharmaceutics15020443
Ilić T, Đoković J, Nikolić I, Mitrović J, Pantelić I, Savić S, Savić M. Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation. in Pharmaceutics. 2023;15(2).
doi:10.3390/pharmaceutics15020443 .
Ilić, Tanja, Đoković, Jelena, Nikolić, Ines, Mitrović, Jelena, Pantelić, Ivana, Savić, Snežana, Savić, Miroslav, "Parenteral Lipid-Based Nanoparticles for CNS Disorders: Integrating Various Facets of Preclinical Evaluation towards More Effective Clinical Translation" in Pharmaceutics, 15, no. 2 (2023),
https://doi.org/10.3390/pharmaceutics15020443 . .
5
2

Sizing up the nanomedicines: a thorough examination of techniques and data interpretation

Nikolić, Ines; Đoković, Jelena; Mehn, Dora; Guerrini, Giuditta; Colpo, Pascal; Jordan, Olivier; Savić, Snežana; Borchard, Gerrit

(French Society for Nanomedicine (SFNano), 2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Đoković, Jelena
AU  - Mehn, Dora
AU  - Guerrini, Giuditta
AU  - Colpo, Pascal
AU  - Jordan, Olivier
AU  - Savić, Snežana
AU  - Borchard, Gerrit
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5427
AB  - Size is a universal and first in mind property relevant for nanomedicine/nanomaterial
characterization, representing the most suitable measurand. However, due to the acknowledged
lack of standardized protocols that are able to provide reliable results, especially in the
biorelevant context, researchers often engage with the procedures that are successful in
acquiring data, but not necessarily the correct ones. ...
PB  - French Society for Nanomedicine (SFNano)
C3  - 9th SFNano annual meeting; December 4th - 6th, Montpellier, France
T1  - Sizing up the nanomedicines: a thorough examination of techniques and data interpretation
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5427
ER  - 
@conference{
author = "Nikolić, Ines and Đoković, Jelena and Mehn, Dora and Guerrini, Giuditta and Colpo, Pascal and Jordan, Olivier and Savić, Snežana and Borchard, Gerrit",
year = "2023",
abstract = "Size is a universal and first in mind property relevant for nanomedicine/nanomaterial
characterization, representing the most suitable measurand. However, due to the acknowledged
lack of standardized protocols that are able to provide reliable results, especially in the
biorelevant context, researchers often engage with the procedures that are successful in
acquiring data, but not necessarily the correct ones. ...",
publisher = "French Society for Nanomedicine (SFNano)",
journal = "9th SFNano annual meeting; December 4th - 6th, Montpellier, France",
title = "Sizing up the nanomedicines: a thorough examination of techniques and data interpretation",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5427"
}
Nikolić, I., Đoković, J., Mehn, D., Guerrini, G., Colpo, P., Jordan, O., Savić, S.,& Borchard, G.. (2023). Sizing up the nanomedicines: a thorough examination of techniques and data interpretation. in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France
French Society for Nanomedicine (SFNano)..
https://hdl.handle.net/21.15107/rcub_farfar_5427
Nikolić I, Đoković J, Mehn D, Guerrini G, Colpo P, Jordan O, Savić S, Borchard G. Sizing up the nanomedicines: a thorough examination of techniques and data interpretation. in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5427 .
Nikolić, Ines, Đoković, Jelena, Mehn, Dora, Guerrini, Giuditta, Colpo, Pascal, Jordan, Olivier, Savić, Snežana, Borchard, Gerrit, "Sizing up the nanomedicines: a thorough examination of techniques and data interpretation" in 9th SFNano annual meeting; December 4th - 6th, Montpellier, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5427 .

Sizing experiments and bio-nano interactions: method matters

Nikolić, Ines; Petrović, Marija; Krupnik, Leondard; Ranđelović, Danijela; Avaro, Jonathan; Neels, Antonia; Borchard, Gerrit; Jordan, Olivier; Đoković, Jelena; Savić, Snežana

(2023)

TY  - CONF
AU  - Nikolić, Ines
AU  - Petrović, Marija
AU  - Krupnik, Leondard
AU  - Ranđelović, Danijela
AU  - Avaro, Jonathan
AU  - Neels, Antonia
AU  - Borchard, Gerrit
AU  - Jordan, Olivier
AU  - Đoković, Jelena
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4571
AB  - INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as promising tools. Increasing number of applications for registration of nanotechnology-enabled pharmaceuticals and many more currently in preclinical or clinical studies raised some questions not only in the field of research and development, but also for regulators. Given the complexity of nanosystems, some specific challenges have been encountered in their characterization, which have not been fully addressed despite respectable research tradition in this field.  Particle size and aggregation potential (especially in complex biological fluids) are some of the critical quality attributes of nanomedicines, being important in the context of physical stability of the colloidal system, and in terms of its safety profile and in vivo performance. Even though a bright future has been predicted for nanomedicines, some of the posted expectations have not been fully met so far. This might be reflected, at least at some points, in the certain methodological issues that commonly result in in vitro to in vivo translational gaps. This aspect underlines the importance of quality and safety assessment of nanomedicines which has also been recognized by globally leading research and regulatory bodies [1,2]. Therefore, the aim of the presented research was to perform a thorough analysis of the selected nanosystem (nanoemulsion) focusing on size estimation and particle-protein interaction applying several techniques, highlighting important factors for a reliable analysis.
METHODLOGY
Materials
As a model nanosystem, previously developed nanoemulsion was used, containing medium-chain triglycerides (Mygliol 812, Fagron) as the oil phase, combination of polysorbate 80 (Acros Organics) and soybean lecithin (Lipoid S-75, Lipoid) as stabilizes, and highly purified water as the water phase. For protein interaction assessment, human serum albumin was used (HSA, Sigma Aldrich).
Methods
Nanoemulsion preparation
Nanoemulsion was prepared via spontaneous emulsification, by dropwise addition of the mixture of the oil and stabilizers to the water phase under constant stirring. For nanoparticle-protein interaction assesment, nanoemulsion was incubated (1h, 37 °C) with HSA in the final concentration of 2.5 mg/ml. 
Sizing experiments – dynamic light scattering
Size and size distribution (per se and in biorelevant environment) were evaluated applying batch mode dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, UK), following the NCL guidance [3]. Intensity-based average hydrodynamic diameter (Z-ave) and polydispersity index (PDI) were analysed in line with relevant parameters of the method. 
Atomic force microscopy (AFM)
Additional sizing analysis and morphological evaluation of the sample were performed applying AFM as a high-resolution technique. AFM analysis of the samples was performed by NTEGRA Prima atomic force microscope (NT-MDT, Moscow, Russia). Intermittent-contact AFM mode was applied using NT-MDT NSGO1 silicon, N-type, antimony doped cantilevers with Au reflective coating. Sample dilution corresponded to the optimal one selected for DLS, and 10 μl of the dilution was placed to the high-quality silica discs (Highest Grade V1 Mica Discs, Ted Pella Inc.) and dried in vacuum. Experiments were performed in the air, in contactless mode. Topographic images and “signal-error” images were collected, AFM images were created and analyzed with the software Image Analysis 2.2.0 (NT-MDT) and Gwyddion 2.60 (Free and Open Source software, Department of Nanometrology, Czech Metrology Institute).
Small angle X-ray scattering (SAXS)
SAXS experiments were performed with the general idea to analyze the structure of the dispersed nanodroplets more profoundly, and especially interactions in biorelevant surrounding (in contact with HSA). A laboratory X-ray setup was applied (Bruker Nanostar, Bruker AXS GmbH, Karlsruhe, Germany). Here, the Kα-line of a X-ray Cu source with a wavelength of 1.541 Å was used and further monochromated by a X-ray mirror. The beam was collimated to a beam diameter of approximately 0.4 mm using three pinholes. The sample-detector distance was set to 107 cm, which lead to a q-range of 0.07 ≤ q ≤ 2.3 nm-1. Calibration of the scattering vector q and estimation of the instrumental resolution of Δq = 0.25 nm-1 was done by measuring the first diffraction peak of a silver behenate sample. The scattered intensity was measured with an avalanche-based detector (VÅNTEC-2000, Bruker AXS). The transmitted part of the beam was determined using a home-made semi-transparent beam stop. The scattered intensity was extracted, radially averaged and integrated over all q-values using the Bruker software DIF-FRAC.EVA (Bruker AXS, version 4.1). The 1D data was transmission corrected and then background subtracted from the scattering of the solvent and the capillary using Matlab 2022.
RESULTS AND DISCUSSION
When applying DLS, as a preliminary technique, primary attention was put on the selection of optimal dilution level for the measurement, analyzing attenuation factor, count rate and intercept of the correlation function in different dilution ratios and with different dilution media (water, PBS 7.4 and 10 mM NaCl), and dilution 1:100 (v/v) was marked as the optimal one. However, significant differences in obtained nanodroplet size was observed depending on the type of medium. When water was used as a dilution medium, significantly higher Z-ave values were obtained (83.71±0.86 nm) compared to the situations where PBS 7.4 (73.50±0.75nm) or 10 mM NaCl (76.59±0.50nm) were used as dilution medium, indicating how sample preparation protocol might be crucial. Even though DLS was not sensitive enough to detect any interaction with HSA (no significant difference in terms of Z-ave and PDI compared to the results obtained in the same dilution medium without HSA), AFM captured qualitative difference in the droplet topography (Figure 1), raising ides on nanoemulsion interfacial interaction with HSA and increased aggregation potential. Further on, SAXS confirmed the existence of a bilayer structure as indicated by a prominent correlation peak at around 1 nm-1, which corresponds to a bilayer thickness of around 6.2 nm. SAXS (Figure 2; probably corresponding to the lecithin formations at the interface). It may be assumed that the bilayer structure changes its structure when mixed with HSA. 
CONCLUSION
In this research, it has been demonstrated how important is to carefully select measurement conditions even for DLS -commonly used and the only standardized methods, in order to keep the measurements meaningful. Further on, not every method is capable of detecting some specific bio-nano interactions. Aiming to generate reliable datasets, condition sine qua non is to perform complementary techniques with increasing complexity. Further experimental segments should cover additional evaluation (e.g. analytical ultracentrifugation, thermal analysis, interfacial properties assessment, electron microscopy) that would shed light on bio-nano interactions important for in vivo fate of the nanosystems.
C3  - 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France
T1  - Sizing experiments and bio-nano interactions: method matters
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4571
ER  - 
@conference{
author = "Nikolić, Ines and Petrović, Marija and Krupnik, Leondard and Ranđelović, Danijela and Avaro, Jonathan and Neels, Antonia and Borchard, Gerrit and Jordan, Olivier and Đoković, Jelena and Savić, Snežana",
year = "2023",
abstract = "INTRODUCTION
Physicochemical properties of many active ingredients jeopardize their pharmacological activity. To overcome identified obstacles, nanosystems as carriers for delivery of actives have been recognized as promising tools. Increasing number of applications for registration of nanotechnology-enabled pharmaceuticals and many more currently in preclinical or clinical studies raised some questions not only in the field of research and development, but also for regulators. Given the complexity of nanosystems, some specific challenges have been encountered in their characterization, which have not been fully addressed despite respectable research tradition in this field.  Particle size and aggregation potential (especially in complex biological fluids) are some of the critical quality attributes of nanomedicines, being important in the context of physical stability of the colloidal system, and in terms of its safety profile and in vivo performance. Even though a bright future has been predicted for nanomedicines, some of the posted expectations have not been fully met so far. This might be reflected, at least at some points, in the certain methodological issues that commonly result in in vitro to in vivo translational gaps. This aspect underlines the importance of quality and safety assessment of nanomedicines which has also been recognized by globally leading research and regulatory bodies [1,2]. Therefore, the aim of the presented research was to perform a thorough analysis of the selected nanosystem (nanoemulsion) focusing on size estimation and particle-protein interaction applying several techniques, highlighting important factors for a reliable analysis.
METHODLOGY
Materials
As a model nanosystem, previously developed nanoemulsion was used, containing medium-chain triglycerides (Mygliol 812, Fagron) as the oil phase, combination of polysorbate 80 (Acros Organics) and soybean lecithin (Lipoid S-75, Lipoid) as stabilizes, and highly purified water as the water phase. For protein interaction assessment, human serum albumin was used (HSA, Sigma Aldrich).
Methods
Nanoemulsion preparation
Nanoemulsion was prepared via spontaneous emulsification, by dropwise addition of the mixture of the oil and stabilizers to the water phase under constant stirring. For nanoparticle-protein interaction assesment, nanoemulsion was incubated (1h, 37 °C) with HSA in the final concentration of 2.5 mg/ml. 
Sizing experiments – dynamic light scattering
Size and size distribution (per se and in biorelevant environment) were evaluated applying batch mode dynamic light scattering (DLS, Zetasizer Nano ZS90, Malvern Instruments, UK), following the NCL guidance [3]. Intensity-based average hydrodynamic diameter (Z-ave) and polydispersity index (PDI) were analysed in line with relevant parameters of the method. 
Atomic force microscopy (AFM)
Additional sizing analysis and morphological evaluation of the sample were performed applying AFM as a high-resolution technique. AFM analysis of the samples was performed by NTEGRA Prima atomic force microscope (NT-MDT, Moscow, Russia). Intermittent-contact AFM mode was applied using NT-MDT NSGO1 silicon, N-type, antimony doped cantilevers with Au reflective coating. Sample dilution corresponded to the optimal one selected for DLS, and 10 μl of the dilution was placed to the high-quality silica discs (Highest Grade V1 Mica Discs, Ted Pella Inc.) and dried in vacuum. Experiments were performed in the air, in contactless mode. Topographic images and “signal-error” images were collected, AFM images were created and analyzed with the software Image Analysis 2.2.0 (NT-MDT) and Gwyddion 2.60 (Free and Open Source software, Department of Nanometrology, Czech Metrology Institute).
Small angle X-ray scattering (SAXS)
SAXS experiments were performed with the general idea to analyze the structure of the dispersed nanodroplets more profoundly, and especially interactions in biorelevant surrounding (in contact with HSA). A laboratory X-ray setup was applied (Bruker Nanostar, Bruker AXS GmbH, Karlsruhe, Germany). Here, the Kα-line of a X-ray Cu source with a wavelength of 1.541 Å was used and further monochromated by a X-ray mirror. The beam was collimated to a beam diameter of approximately 0.4 mm using three pinholes. The sample-detector distance was set to 107 cm, which lead to a q-range of 0.07 ≤ q ≤ 2.3 nm-1. Calibration of the scattering vector q and estimation of the instrumental resolution of Δq = 0.25 nm-1 was done by measuring the first diffraction peak of a silver behenate sample. The scattered intensity was measured with an avalanche-based detector (VÅNTEC-2000, Bruker AXS). The transmitted part of the beam was determined using a home-made semi-transparent beam stop. The scattered intensity was extracted, radially averaged and integrated over all q-values using the Bruker software DIF-FRAC.EVA (Bruker AXS, version 4.1). The 1D data was transmission corrected and then background subtracted from the scattering of the solvent and the capillary using Matlab 2022.
RESULTS AND DISCUSSION
When applying DLS, as a preliminary technique, primary attention was put on the selection of optimal dilution level for the measurement, analyzing attenuation factor, count rate and intercept of the correlation function in different dilution ratios and with different dilution media (water, PBS 7.4 and 10 mM NaCl), and dilution 1:100 (v/v) was marked as the optimal one. However, significant differences in obtained nanodroplet size was observed depending on the type of medium. When water was used as a dilution medium, significantly higher Z-ave values were obtained (83.71±0.86 nm) compared to the situations where PBS 7.4 (73.50±0.75nm) or 10 mM NaCl (76.59±0.50nm) were used as dilution medium, indicating how sample preparation protocol might be crucial. Even though DLS was not sensitive enough to detect any interaction with HSA (no significant difference in terms of Z-ave and PDI compared to the results obtained in the same dilution medium without HSA), AFM captured qualitative difference in the droplet topography (Figure 1), raising ides on nanoemulsion interfacial interaction with HSA and increased aggregation potential. Further on, SAXS confirmed the existence of a bilayer structure as indicated by a prominent correlation peak at around 1 nm-1, which corresponds to a bilayer thickness of around 6.2 nm. SAXS (Figure 2; probably corresponding to the lecithin formations at the interface). It may be assumed that the bilayer structure changes its structure when mixed with HSA. 
CONCLUSION
In this research, it has been demonstrated how important is to carefully select measurement conditions even for DLS -commonly used and the only standardized methods, in order to keep the measurements meaningful. Further on, not every method is capable of detecting some specific bio-nano interactions. Aiming to generate reliable datasets, condition sine qua non is to perform complementary techniques with increasing complexity. Further experimental segments should cover additional evaluation (e.g. analytical ultracentrifugation, thermal analysis, interfacial properties assessment, electron microscopy) that would shed light on bio-nano interactions important for in vivo fate of the nanosystems.",
journal = "4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France",
title = "Sizing experiments and bio-nano interactions: method matters",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4571"
}
Nikolić, I., Petrović, M., Krupnik, L., Ranđelović, D., Avaro, J., Neels, A., Borchard, G., Jordan, O., Đoković, J.,& Savić, S.. (2023). Sizing experiments and bio-nano interactions: method matters. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France.
https://hdl.handle.net/21.15107/rcub_farfar_4571
Nikolić I, Petrović M, Krupnik L, Ranđelović D, Avaro J, Neels A, Borchard G, Jordan O, Đoković J, Savić S. Sizing experiments and bio-nano interactions: method matters. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4571 .
Nikolić, Ines, Petrović, Marija, Krupnik, Leondard, Ranđelović, Danijela, Avaro, Jonathan, Neels, Antonia, Borchard, Gerrit, Jordan, Olivier, Đoković, Jelena, Savić, Snežana, "Sizing experiments and bio-nano interactions: method matters" in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4571 .

Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer

Đoković, Jelena; Demisli, Sotiria; Papadimitriou, Vassiliki; Savić, Snežana

(2023)

TY  - CONF
AU  - Đoković, Jelena
AU  - Demisli, Sotiria
AU  - Papadimitriou, Vassiliki
AU  - Savić, Snežana
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4572
AB  - INTRODUCTION
Nanoemulsions (NEs) offer a flexible platform for drug delivery via several administration routes. Rapid plasma clearance brought on by interactions with plasma proteins and the activation of the mononuclear phagocytic system is the greatest challenge NEs face after parenteral administration. PEGylation, or adding PEGylated phospholipids to the stabilizing layer of the NEs, is one method for ensuring that droplets circulate for a longer period of time. It is crucial to select the optimum concentration of the PEGylated in order to maintain the necessary physicochemical properties of NEs while providing appropriate surface coverage with the PEG chains. Curcumin is a model active that has been found to be localized in the stabilizing layer of NEs (1-3) and offers a wide range of potential health benefits, but due to its short plasma half-life, new strategies for enhancing bioavailability are required. The purpose of this study is to investigate the effects of various PEGylated phospholipid (PEG2000-DSPE) concentrations on the structural properties of NEs with an active placed in the stabilizing layer.
PREPARATION OF NANOEMULSIONS
All the NEs were prepared using the high pressure homogenization technique. The aqueous phase (glycerol, polysorbate 80, sodium oleate and highly purified water) was added to the oil phase (soybean oil, medium chain triglycerides, soybean lecithin, buthylhydroxytoluene, curcumin and 0.1%/0.3%/0.6% PEG2000-DSPE) and mixed at 11000rpm for 1 min on rotor stator homogenizer (IKA Ultra-Turrax T25 digital, IKA-Werke GmbH & Co. KG, Staufen, Germany), and then further processed at 800 bar for 10 discontinued cycles (EmulsiFlex-C3, Avestin Inc., Ottawa,ON, Canada) to obtain CS21, CS23 and CS26 formulations.
NANOEMULSION DROPLET SIZE
The droplet size was assessed through the dynamic light scattering method and presented as mean droplet size (Z-ave) and polydispersity index (PDI), after diluting the NEs 1:500 (v/v) in highly purified water.
ELECTRON PARAMAGNETIC RESONANCE (EPR) SPECTROSCOPY
For this study three amphiphilic fatty acid derivatives labeled at different positions of the aliphatic chain (5-DSA, 12-DSA and 16-DSA) were used to probe the dynamics of the membrane at different depths. Stock solutions of the spin probes were prepared in absolute ethanol at 1mM concentration. Subsequently, 15 µl of the stock solutions were evaporated and then incubated with 1 ml of the NE sample in final concentration of 0.015 mM. The resulting spectra was analyzed in terms of rotational correlation time (τR), order parameter (S) and isotropic hyperfine constant (αN).
RESULTS AND DISCUSION
All of the formulations had average droplet sizes between 95 and 103 nm and PDI values under 0.25, which indicated that they were suitable for parenteral administration.
The results of the EPR investigation showed that the stabilizing layer changed as the amount of PEGylated phospholipids increased, indicating that the PEGylation threshold has not yet been reached in the stabilizing layer.
The EPR research also showed that the 5-DSA spin probe's spectra were significantly affected by the addition of various PEGylated phospholipid concentrations (Figure 1). This indicates that the portion of the stabilizing layer nearest to the aqueous phase was the one most affected by the increase in the PEGylated phospholipid concentration. Table 1 provides the calculated values for the spectrum parameters. The mobility of the spin-probe and the time it takes for the spin-probe to make a full rotation is reflected in the τR parameter, which was changed the most, compared to the other parameters, by the variations in the PEGylated phospholipid content. A formulation with the most rigid stabilizing layer had the largest τR values, which, in this instance, was the formulation with 0.1% PEG2000-DSPE. It's interesting to note that the addition of PEGylated phospholipid had the opposite effect of strengthening the stabilizing layer. Further PEG2000-DSPE addition appeared to result in nanoemulsions with a less rigid stabilizing layer, possibly indicating that larger concentrations of the PEGylating agent lead to interface destabilization. The interactions between the curcumin, a symmetrical molecule with two aromatic ring systems and a bent conformation located in the stabilizing layer and the extra stabilizer are likely responsible for this.
The other two spin probes (12-DSA and 16-DSA) provide information about the stabilizing layer located closer to the oil core. Based on the data provided in Table 1 it can be inferred that the PEGylation mostly affects the stabilizing layer's areas closest to the aqueous interface, leaving the parts closer to the oil core largely not impacted.
CONCLUSION
This study demonstrates that one of the key elements in assessing how PEGylation affects the NE system is the active's localization. To pick the concentration of the PEGylated phospholipid that will offer the best surface coverage without compromising the integrity of the interface, additional considerations must be addressed in the event of an active situated in the stabilizing layer. In this instance, it may be hypothesized that the lowest PEG2000-DSPE concentration of 0.1%, CS21, will produce NEs that can slow down curcumin release the most compared to the other two formulations. Additionally, given that further addition of the PEGylated phospholipid causes the formation of less rigid stabilizing layer, further inquiries should be made to see the impact of these changes on the interactions with plasma proteins and biological fate of the droplets upon administration.
C3  - 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France
T1  - Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4572
ER  - 
@conference{
author = "Đoković, Jelena and Demisli, Sotiria and Papadimitriou, Vassiliki and Savić, Snežana",
year = "2023",
abstract = "INTRODUCTION
Nanoemulsions (NEs) offer a flexible platform for drug delivery via several administration routes. Rapid plasma clearance brought on by interactions with plasma proteins and the activation of the mononuclear phagocytic system is the greatest challenge NEs face after parenteral administration. PEGylation, or adding PEGylated phospholipids to the stabilizing layer of the NEs, is one method for ensuring that droplets circulate for a longer period of time. It is crucial to select the optimum concentration of the PEGylated in order to maintain the necessary physicochemical properties of NEs while providing appropriate surface coverage with the PEG chains. Curcumin is a model active that has been found to be localized in the stabilizing layer of NEs (1-3) and offers a wide range of potential health benefits, but due to its short plasma half-life, new strategies for enhancing bioavailability are required. The purpose of this study is to investigate the effects of various PEGylated phospholipid (PEG2000-DSPE) concentrations on the structural properties of NEs with an active placed in the stabilizing layer.
PREPARATION OF NANOEMULSIONS
All the NEs were prepared using the high pressure homogenization technique. The aqueous phase (glycerol, polysorbate 80, sodium oleate and highly purified water) was added to the oil phase (soybean oil, medium chain triglycerides, soybean lecithin, buthylhydroxytoluene, curcumin and 0.1%/0.3%/0.6% PEG2000-DSPE) and mixed at 11000rpm for 1 min on rotor stator homogenizer (IKA Ultra-Turrax T25 digital, IKA-Werke GmbH & Co. KG, Staufen, Germany), and then further processed at 800 bar for 10 discontinued cycles (EmulsiFlex-C3, Avestin Inc., Ottawa,ON, Canada) to obtain CS21, CS23 and CS26 formulations.
NANOEMULSION DROPLET SIZE
The droplet size was assessed through the dynamic light scattering method and presented as mean droplet size (Z-ave) and polydispersity index (PDI), after diluting the NEs 1:500 (v/v) in highly purified water.
ELECTRON PARAMAGNETIC RESONANCE (EPR) SPECTROSCOPY
For this study three amphiphilic fatty acid derivatives labeled at different positions of the aliphatic chain (5-DSA, 12-DSA and 16-DSA) were used to probe the dynamics of the membrane at different depths. Stock solutions of the spin probes were prepared in absolute ethanol at 1mM concentration. Subsequently, 15 µl of the stock solutions were evaporated and then incubated with 1 ml of the NE sample in final concentration of 0.015 mM. The resulting spectra was analyzed in terms of rotational correlation time (τR), order parameter (S) and isotropic hyperfine constant (αN).
RESULTS AND DISCUSION
All of the formulations had average droplet sizes between 95 and 103 nm and PDI values under 0.25, which indicated that they were suitable for parenteral administration.
The results of the EPR investigation showed that the stabilizing layer changed as the amount of PEGylated phospholipids increased, indicating that the PEGylation threshold has not yet been reached in the stabilizing layer.
The EPR research also showed that the 5-DSA spin probe's spectra were significantly affected by the addition of various PEGylated phospholipid concentrations (Figure 1). This indicates that the portion of the stabilizing layer nearest to the aqueous phase was the one most affected by the increase in the PEGylated phospholipid concentration. Table 1 provides the calculated values for the spectrum parameters. The mobility of the spin-probe and the time it takes for the spin-probe to make a full rotation is reflected in the τR parameter, which was changed the most, compared to the other parameters, by the variations in the PEGylated phospholipid content. A formulation with the most rigid stabilizing layer had the largest τR values, which, in this instance, was the formulation with 0.1% PEG2000-DSPE. It's interesting to note that the addition of PEGylated phospholipid had the opposite effect of strengthening the stabilizing layer. Further PEG2000-DSPE addition appeared to result in nanoemulsions with a less rigid stabilizing layer, possibly indicating that larger concentrations of the PEGylating agent lead to interface destabilization. The interactions between the curcumin, a symmetrical molecule with two aromatic ring systems and a bent conformation located in the stabilizing layer and the extra stabilizer are likely responsible for this.
The other two spin probes (12-DSA and 16-DSA) provide information about the stabilizing layer located closer to the oil core. Based on the data provided in Table 1 it can be inferred that the PEGylation mostly affects the stabilizing layer's areas closest to the aqueous interface, leaving the parts closer to the oil core largely not impacted.
CONCLUSION
This study demonstrates that one of the key elements in assessing how PEGylation affects the NE system is the active's localization. To pick the concentration of the PEGylated phospholipid that will offer the best surface coverage without compromising the integrity of the interface, additional considerations must be addressed in the event of an active situated in the stabilizing layer. In this instance, it may be hypothesized that the lowest PEG2000-DSPE concentration of 0.1%, CS21, will produce NEs that can slow down curcumin release the most compared to the other two formulations. Additionally, given that further addition of the PEGylated phospholipid causes the formation of less rigid stabilizing layer, further inquiries should be made to see the impact of these changes on the interactions with plasma proteins and biological fate of the droplets upon administration.",
journal = "4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France",
title = "Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4572"
}
Đoković, J., Demisli, S., Papadimitriou, V.,& Savić, S.. (2023). Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France.
https://hdl.handle.net/21.15107/rcub_farfar_4572
Đoković J, Demisli S, Papadimitriou V, Savić S. Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer. in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_4572 .
Đoković, Jelena, Demisli, Sotiria, Papadimitriou, Vassiliki, Savić, Snežana, "Structural analysis of PEGylated nanoemulsions using EPR spectroscopy – the impact of an active compound incorporated in stabilizing layer" in 4th European Conference on Pharmaceutics, 20 - 21 March 2023, Marseille, France (2023),
https://hdl.handle.net/21.15107/rcub_farfar_4572 .

Deciphering ciprofloxacin-induced neurotoxicity: behavioral and molecular profiling of ciprofloxacin treatment in rats

Mirković, Kristina; Aranđelović, Jovana; Kojić, Jana; Stevanović, Vladimir; Batinić, Bojan; Todorović, Vanja; Đoković, Jelena; Santrač, Anja; Major, Tamara; Savić, Miroslav

(European College of Neuropsychopharmacology (ECNP), 2023)

TY  - CONF
AU  - Mirković, Kristina
AU  - Aranđelović, Jovana
AU  - Kojić, Jana
AU  - Stevanović, Vladimir
AU  - Batinić, Bojan
AU  - Todorović, Vanja
AU  - Đoković, Jelena
AU  - Santrač, Anja
AU  - Major, Tamara
AU  - Savić, Miroslav
PY  - 2023
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5521
AB  - Introduction: Ciprofloxacin is a fluoroquinolone antibiotic commonly used to treat various bacterial infections, with a potential to induce adverse mood effects in patients. Since the molecular mechanism of ciprofloxacin-induced neurotoxicity is poorly understood, we aimed to identify behavioral changes and corresponding neurotransmitter pattern after its prolonged administration in rats. We screened for untoward effects of ciprofloxacin on locomotor activity, despair, anhedonia, object recognition memory, and anxiety, as behavioral domains affected in various psychiatric diseases. Methodology: Three-month old male Sprague-Dawley rats were orally gavaged with ciprofloxacin (20 or 100 mg/kg) or solvent (0.5% methyl cellulose solution) each day for 4 weeks (n=80). One group of animals (n=40) passed the open field (OF), novel object recognition test (NORT), and forced swimming test (FST). Another group (n=40) underwent elevated plus maze (EPM) and sucrose preference test (SPT). After the completion of behavioral battery, the prefrontal cortex and cerebrospinal fluid (CSF) were collected. The neurotransmitters and metabolites of the kynurenine pathway were determined in the prefrontal cortex (PFC) through HPLC-MS/MS. Additionally, levels of interleukin-2 (IL-2) in CSF were quantified with Luminex. Behavioral and molecular parameters were analyzed by one-way ANOVA followed by Dunnett post hoc test in GraphPad Prism 9. Results: In FST, the treatment with high dose of ciprofloxacin decreased the swim time compared to control, which could be related to induction of despair-like behavior (p<0.05). The ciprofloxacin treatment did not affect object memory in NORT. In OF, the distance travelled and the number of rotations were not changed after treatment with ciprofloxacin compared to the control group. Further, animals treated with ciprofloxacin did not show changes in parameters in EPM and SPT. The acetylcholine levels in PFC were increased after ciprofloxacin treatment (p<0.05) in comparison with controls, which could be associated with depressed mood states. In line with that, high dose of ciprofloxacin treatment showed the tendency to decrease and increase levels of GABA and dopamine, respectively, but without reaching the statistical significance (p=0.07 and p=0.06). No changes in kynurenine pathway were observed after the treatment. The IL-2 concentration in CSF was increased after prolonged administration of low dose of ciprofloxacin treatment compared to the control levels (p<0.05), which could imply immunological stimulation of T lymphocytes and potential neuroinflammation. Conclusion: The despair behavior after treatment with high dose of ciprofloxacin was accompanied by increased levels of acetylcholine in PFC. Furthermore, the high dose of ciprofloxacin treatment showed tendency to decrease GABA levels, and increase dopamine levels in PFC, which could be connected to psychiatric adverse effects. Nonetheless, further studies are essential to confirm these neurotransmitter changes. On the other hand, the low dose of ciprofloxacin treatment elicited the increase of IL-2, which could be a marker of neuroinflammation-related neurotoxicity. In the future, efforts should be made to examine the role of IL-2 in the interaction of the immune system and the central nervous system, as its potential significance as a biomarker.
PB  - European College of Neuropsychopharmacology (ECNP)
C3  - 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain
T1  - Deciphering ciprofloxacin-induced neurotoxicity: behavioral and molecular profiling of ciprofloxacin treatment in rats
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5521
ER  - 
@conference{
author = "Mirković, Kristina and Aranđelović, Jovana and Kojić, Jana and Stevanović, Vladimir and Batinić, Bojan and Todorović, Vanja and Đoković, Jelena and Santrač, Anja and Major, Tamara and Savić, Miroslav",
year = "2023",
abstract = "Introduction: Ciprofloxacin is a fluoroquinolone antibiotic commonly used to treat various bacterial infections, with a potential to induce adverse mood effects in patients. Since the molecular mechanism of ciprofloxacin-induced neurotoxicity is poorly understood, we aimed to identify behavioral changes and corresponding neurotransmitter pattern after its prolonged administration in rats. We screened for untoward effects of ciprofloxacin on locomotor activity, despair, anhedonia, object recognition memory, and anxiety, as behavioral domains affected in various psychiatric diseases. Methodology: Three-month old male Sprague-Dawley rats were orally gavaged with ciprofloxacin (20 or 100 mg/kg) or solvent (0.5% methyl cellulose solution) each day for 4 weeks (n=80). One group of animals (n=40) passed the open field (OF), novel object recognition test (NORT), and forced swimming test (FST). Another group (n=40) underwent elevated plus maze (EPM) and sucrose preference test (SPT). After the completion of behavioral battery, the prefrontal cortex and cerebrospinal fluid (CSF) were collected. The neurotransmitters and metabolites of the kynurenine pathway were determined in the prefrontal cortex (PFC) through HPLC-MS/MS. Additionally, levels of interleukin-2 (IL-2) in CSF were quantified with Luminex. Behavioral and molecular parameters were analyzed by one-way ANOVA followed by Dunnett post hoc test in GraphPad Prism 9. Results: In FST, the treatment with high dose of ciprofloxacin decreased the swim time compared to control, which could be related to induction of despair-like behavior (p<0.05). The ciprofloxacin treatment did not affect object memory in NORT. In OF, the distance travelled and the number of rotations were not changed after treatment with ciprofloxacin compared to the control group. Further, animals treated with ciprofloxacin did not show changes in parameters in EPM and SPT. The acetylcholine levels in PFC were increased after ciprofloxacin treatment (p<0.05) in comparison with controls, which could be associated with depressed mood states. In line with that, high dose of ciprofloxacin treatment showed the tendency to decrease and increase levels of GABA and dopamine, respectively, but without reaching the statistical significance (p=0.07 and p=0.06). No changes in kynurenine pathway were observed after the treatment. The IL-2 concentration in CSF was increased after prolonged administration of low dose of ciprofloxacin treatment compared to the control levels (p<0.05), which could imply immunological stimulation of T lymphocytes and potential neuroinflammation. Conclusion: The despair behavior after treatment with high dose of ciprofloxacin was accompanied by increased levels of acetylcholine in PFC. Furthermore, the high dose of ciprofloxacin treatment showed tendency to decrease GABA levels, and increase dopamine levels in PFC, which could be connected to psychiatric adverse effects. Nonetheless, further studies are essential to confirm these neurotransmitter changes. On the other hand, the low dose of ciprofloxacin treatment elicited the increase of IL-2, which could be a marker of neuroinflammation-related neurotoxicity. In the future, efforts should be made to examine the role of IL-2 in the interaction of the immune system and the central nervous system, as its potential significance as a biomarker.",
publisher = "European College of Neuropsychopharmacology (ECNP)",
journal = "36th ECPN congress, 7th -10th October 2023, Barcelona, Spain",
title = "Deciphering ciprofloxacin-induced neurotoxicity: behavioral and molecular profiling of ciprofloxacin treatment in rats",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5521"
}
Mirković, K., Aranđelović, J., Kojić, J., Stevanović, V., Batinić, B., Todorović, V., Đoković, J., Santrač, A., Major, T.,& Savić, M.. (2023). Deciphering ciprofloxacin-induced neurotoxicity: behavioral and molecular profiling of ciprofloxacin treatment in rats. in 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain
European College of Neuropsychopharmacology (ECNP)..
https://hdl.handle.net/21.15107/rcub_farfar_5521
Mirković K, Aranđelović J, Kojić J, Stevanović V, Batinić B, Todorović V, Đoković J, Santrač A, Major T, Savić M. Deciphering ciprofloxacin-induced neurotoxicity: behavioral and molecular profiling of ciprofloxacin treatment in rats. in 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain. 2023;.
https://hdl.handle.net/21.15107/rcub_farfar_5521 .
Mirković, Kristina, Aranđelović, Jovana, Kojić, Jana, Stevanović, Vladimir, Batinić, Bojan, Todorović, Vanja, Đoković, Jelena, Santrač, Anja, Major, Tamara, Savić, Miroslav, "Deciphering ciprofloxacin-induced neurotoxicity: behavioral and molecular profiling of ciprofloxacin treatment in rats" in 36th ECPN congress, 7th -10th October 2023, Barcelona, Spain (2023),
https://hdl.handle.net/21.15107/rcub_farfar_5521 .

Physicochemical/structural investigation of lipid nanoparticles with high lecithin amounts loaded with patent protected pyrazoloquinolinone ligand DK-I-60-3

Mitrović, Jelena; Petković, Miloš; Ranđelović, Danijela; Đoković, Jelena; Knutson, Daniel; Cook, James; Savić, Vladimir; Savić, Miroslav; Savić, Snežana

(2022)

TY  - CONF
AU  - Mitrović, Jelena
AU  - Petković, Miloš
AU  - Ranđelović, Danijela
AU  - Đoković, Jelena
AU  - Knutson, Daniel
AU  - Cook, James
AU  - Savić, Vladimir
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4097
AB  - Lipid nanoparticles are being intensively investigated for
the formulation of the drugs with poor solubility substances
(1). They represent colloid dispersions of the particles with
lipid matrix that is solid at room and body temperature.
Because of the low capacity of triglycerides for the drug
substances incorporation, alternatively, high amounts of
lecithin could be added to increase the solubilization (2).
This was used for the incorporation of DK-I-60-3 (7-
methoxy-d3-2-(4-methoxyd3-phenyl)-2,5-dihydro-
3Hpyrazolo[4,3-c]quinolin-3-one), novel deuterated
pyrazoloquinolinone ligand, with very low solubility in
water as well as in oils (3,4). However, because of
amphiphilic nature of lecithin, its localization within
nanoparticles should be analyzed, especially with respect
to stability, drug loading capacity and drug localization,
because it may additionally influence the drug release
mechanism (2).
C3  - 13th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 28-31 March 2022, Rotterdam, Netherlands
T1  - Physicochemical/structural investigation of lipid nanoparticles with high lecithin amounts loaded with patent protected pyrazoloquinolinone ligand DK-I-60-3
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4097
ER  - 
@conference{
author = "Mitrović, Jelena and Petković, Miloš and Ranđelović, Danijela and Đoković, Jelena and Knutson, Daniel and Cook, James and Savić, Vladimir and Savić, Miroslav and Savić, Snežana",
year = "2022",
abstract = "Lipid nanoparticles are being intensively investigated for
the formulation of the drugs with poor solubility substances
(1). They represent colloid dispersions of the particles with
lipid matrix that is solid at room and body temperature.
Because of the low capacity of triglycerides for the drug
substances incorporation, alternatively, high amounts of
lecithin could be added to increase the solubilization (2).
This was used for the incorporation of DK-I-60-3 (7-
methoxy-d3-2-(4-methoxyd3-phenyl)-2,5-dihydro-
3Hpyrazolo[4,3-c]quinolin-3-one), novel deuterated
pyrazoloquinolinone ligand, with very low solubility in
water as well as in oils (3,4). However, because of
amphiphilic nature of lecithin, its localization within
nanoparticles should be analyzed, especially with respect
to stability, drug loading capacity and drug localization,
because it may additionally influence the drug release
mechanism (2).",
journal = "13th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 28-31 March 2022, Rotterdam, Netherlands",
title = "Physicochemical/structural investigation of lipid nanoparticles with high lecithin amounts loaded with patent protected pyrazoloquinolinone ligand DK-I-60-3",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4097"
}
Mitrović, J., Petković, M., Ranđelović, D., Đoković, J., Knutson, D., Cook, J., Savić, V., Savić, M.,& Savić, S.. (2022). Physicochemical/structural investigation of lipid nanoparticles with high lecithin amounts loaded with patent protected pyrazoloquinolinone ligand DK-I-60-3. in 13th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 28-31 March 2022, Rotterdam, Netherlands.
https://hdl.handle.net/21.15107/rcub_farfar_4097
Mitrović J, Petković M, Ranđelović D, Đoković J, Knutson D, Cook J, Savić V, Savić M, Savić S. Physicochemical/structural investigation of lipid nanoparticles with high lecithin amounts loaded with patent protected pyrazoloquinolinone ligand DK-I-60-3. in 13th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 28-31 March 2022, Rotterdam, Netherlands. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4097 .
Mitrović, Jelena, Petković, Miloš, Ranđelović, Danijela, Đoković, Jelena, Knutson, Daniel, Cook, James, Savić, Vladimir, Savić, Miroslav, Savić, Snežana, "Physicochemical/structural investigation of lipid nanoparticles with high lecithin amounts loaded with patent protected pyrazoloquinolinone ligand DK-I-60-3" in 13th World meeting on pharmaceutics, biopharmaceutics and pharmaceutical technology, 28-31 March 2022, Rotterdam, Netherlands (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4097 .

A proposal of innovative injectability assessment method for intravenous formulations - case study on PEGylated nanoemulsions

Đoković, Jelena; Savić, Sanela; Cekić, Nebojša; Savić, Snežana

(2022)

TY  - CONF
AU  - Đoković, Jelena
AU  - Savić, Sanela
AU  - Cekić, Nebojša
AU  - Savić, Snežana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4269
AB  - 1.	INTRODUCTION
Syringeability and injectability are recognised as fundamental performance parameters / critical quality attributes of any parenteral dosage form. Syringeability refers to the ability of an injectable preparation to transfer from a vial through a hypodermic needle prior an injection, while injectability is defined as the force, or pressure, required to inject the formulation from a syringe-needle system into the tissue [1]. When developing drug delivery systems, the priority is usually the release kinetics, biocompatibility or other factors that may come in conflict with the optimal parameters for the applicability of those systems [2]. The aim of this research was to develop a method that could be used for injectability assessment of the intravenous formulations and the application of this method on curcumin-loaded PEGylated nanoemulsions (NEs) in order to gage the impact of PEGylation on NEs injectability.
2. MATERIALS AND METHODS
2.1. Nanoemulsion preparation
Nanoemulsions were prepared using high pressure homogenization method. The aqueous phase (glycerol, polysorbate 80, sodium oleate and highly purified water) was added into the oil phase (soybean oil, soybean lecithin, medium chain triglycerides, butylhydroxytoluene, benzyl alcohol, curcumin and PEGylated phospholipid – PEG2000-DSPE in 0.1 %, 0.3 % or 0.6 % concentrations) and mixed using rotor-stator homogenizer (IKA Ultra-Turrax® T25 digital, IKA®-Werke GmbH and Co. KG, Staufen, Germany), and further processed on high pressure homogenizer (EmulsiFlex-C3, Avestin Inc., Canada) at 800 bar for 10 discontinued cycles. The non PEGylated formulation was marked as CS, and the PEGylated ones were marked S1, S3 and S6, referring to the PEG2000-DSPE concentration.
2.2. Physicochemical characterization
The NEs droplet size (Z-Ave) and droplet size distribution (PDI) were determined with Zetasizer Nano ZS90 (Malvern Instruments Ltd., Worcestershire). Rheological analysis was performed using MCR 302 air-bearing rheometer (Anton Paar, Graz, Austria) equipped with coaxial cylinders system (CC27 measuring bob with C-PTD 180/Air) with sheer rate range of 0.1-100 s-1 at 20°C.
2.3. Injectabilty assesment
The injectability of the NEs was expressed as force (N) needed to extrude the NE in the function of the extruded volume (ml). About 10 ml of the NE was loaded into the 10 ml syringe and extruded through the 25 G scalp vein infusion set (Romed, Wilnis, Netherlands) into the blood mimicking solution, circulating through pump at 4 ml/min, in order to assess the NEs’ performance in the prospective intravenous administration. The NEs were extruded at 1 mm/s croshead speed of the loading cell of the texure analyzer (EZ-LX Compact Table-Top Testing Machine, Shimadzu, Japan) with the TrapeziumX software version 1.5 used for data collection and analysis
3. RESULTS AND DISCUSSION
3.1. Physicochemical characterization
The NEs have average size of about 100 nm, with the PDI values below 0.20, indicating suitability for intravenous application. It could be observed from Fig. 1 that the addition of PEGylated phospholipids caused an increase in NE viscosity, as could be expected given that the polyethylene glycols are used in parenteral suspensions as stabilizing - rheology modifying agents [3].
3.2. Injectability assessment
The injectability assessment was performed with syringe-needle system used in our laboratory for intravenous administration in in vivo animal studies. As blood-mimicking solution, 36.6 %, v/v, glycerol solution was used [4]. It could be observed from Fig. 2 that the injectability of NEs depended on their viscosity, with the higher pressure needed to extrude the formulations with the higher PEG2000-DSPE concentration. Even though, to the best of our knowledge, there are no studies investigating the injectability of the intravenous preparations, based on some previous research on subcutaneous model [5], it is recommended the maximum force used to inject the formulations should be kept about 20 N, which would eliminate S3 and S6 from further investigation (Fig. 2).
4. CONCLUSION
The injectability method used in this research proved as a useful tool in screening formulations adequate for prospective intravenous use.
5. REFERENCES
1.	Cilurzo, F., et al. Injectability Evaluation: An Open Issue. AAPS PharmSciTech, 2011. 12(2): 604-609.
2.	Sarmadi, M., et al. Modeling, design, and machine learning-based framework for optimal injectability of microparticle-based drug formulations. Science advances, 2020. 6: eabb6594.
3.	Gullapalli, R. P., Mazzitelli, C. L. Polyethylene glycols in oral and parenteral formulations—A critical review. International Journal of Pharmaceutics, 2015. 496(2): 219-239.
4.	Yousif, M. Y., et al.. Deriving a blood-mimicking fluid for particle image velocimetry in Sylgard-184 vascular models. In Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2009 (pp. 1412-1415
5.	Watt, R. P., et al. (2019). Injectability as a function of viscosity and dosing materials for subcutaneous administration. International Journal of Pharmaceutics, 2019:554, 376-386.
ACKNOWLEDGMENT
This research was funded by the MESDT, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-68/2022-14/200161 and supported by the Science Fund of the Republic of Serbia, GRANT No 7749108, Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platform - NanoCellEmоCog.
C3  - 9th BBBB International conference on pharmaceutical sciences; 15th - 17th September, Ljubljana, Slovenia
T1  - A proposal of innovative injectability assessment method for intravenous formulations - case study on PEGylated nanoemulsions
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4269
ER  - 
@conference{
author = "Đoković, Jelena and Savić, Sanela and Cekić, Nebojša and Savić, Snežana",
year = "2022",
abstract = "1.	INTRODUCTION
Syringeability and injectability are recognised as fundamental performance parameters / critical quality attributes of any parenteral dosage form. Syringeability refers to the ability of an injectable preparation to transfer from a vial through a hypodermic needle prior an injection, while injectability is defined as the force, or pressure, required to inject the formulation from a syringe-needle system into the tissue [1]. When developing drug delivery systems, the priority is usually the release kinetics, biocompatibility or other factors that may come in conflict with the optimal parameters for the applicability of those systems [2]. The aim of this research was to develop a method that could be used for injectability assessment of the intravenous formulations and the application of this method on curcumin-loaded PEGylated nanoemulsions (NEs) in order to gage the impact of PEGylation on NEs injectability.
2. MATERIALS AND METHODS
2.1. Nanoemulsion preparation
Nanoemulsions were prepared using high pressure homogenization method. The aqueous phase (glycerol, polysorbate 80, sodium oleate and highly purified water) was added into the oil phase (soybean oil, soybean lecithin, medium chain triglycerides, butylhydroxytoluene, benzyl alcohol, curcumin and PEGylated phospholipid – PEG2000-DSPE in 0.1 %, 0.3 % or 0.6 % concentrations) and mixed using rotor-stator homogenizer (IKA Ultra-Turrax® T25 digital, IKA®-Werke GmbH and Co. KG, Staufen, Germany), and further processed on high pressure homogenizer (EmulsiFlex-C3, Avestin Inc., Canada) at 800 bar for 10 discontinued cycles. The non PEGylated formulation was marked as CS, and the PEGylated ones were marked S1, S3 and S6, referring to the PEG2000-DSPE concentration.
2.2. Physicochemical characterization
The NEs droplet size (Z-Ave) and droplet size distribution (PDI) were determined with Zetasizer Nano ZS90 (Malvern Instruments Ltd., Worcestershire). Rheological analysis was performed using MCR 302 air-bearing rheometer (Anton Paar, Graz, Austria) equipped with coaxial cylinders system (CC27 measuring bob with C-PTD 180/Air) with sheer rate range of 0.1-100 s-1 at 20°C.
2.3. Injectabilty assesment
The injectability of the NEs was expressed as force (N) needed to extrude the NE in the function of the extruded volume (ml). About 10 ml of the NE was loaded into the 10 ml syringe and extruded through the 25 G scalp vein infusion set (Romed, Wilnis, Netherlands) into the blood mimicking solution, circulating through pump at 4 ml/min, in order to assess the NEs’ performance in the prospective intravenous administration. The NEs were extruded at 1 mm/s croshead speed of the loading cell of the texure analyzer (EZ-LX Compact Table-Top Testing Machine, Shimadzu, Japan) with the TrapeziumX software version 1.5 used for data collection and analysis
3. RESULTS AND DISCUSSION
3.1. Physicochemical characterization
The NEs have average size of about 100 nm, with the PDI values below 0.20, indicating suitability for intravenous application. It could be observed from Fig. 1 that the addition of PEGylated phospholipids caused an increase in NE viscosity, as could be expected given that the polyethylene glycols are used in parenteral suspensions as stabilizing - rheology modifying agents [3].
3.2. Injectability assessment
The injectability assessment was performed with syringe-needle system used in our laboratory for intravenous administration in in vivo animal studies. As blood-mimicking solution, 36.6 %, v/v, glycerol solution was used [4]. It could be observed from Fig. 2 that the injectability of NEs depended on their viscosity, with the higher pressure needed to extrude the formulations with the higher PEG2000-DSPE concentration. Even though, to the best of our knowledge, there are no studies investigating the injectability of the intravenous preparations, based on some previous research on subcutaneous model [5], it is recommended the maximum force used to inject the formulations should be kept about 20 N, which would eliminate S3 and S6 from further investigation (Fig. 2).
4. CONCLUSION
The injectability method used in this research proved as a useful tool in screening formulations adequate for prospective intravenous use.
5. REFERENCES
1.	Cilurzo, F., et al. Injectability Evaluation: An Open Issue. AAPS PharmSciTech, 2011. 12(2): 604-609.
2.	Sarmadi, M., et al. Modeling, design, and machine learning-based framework for optimal injectability of microparticle-based drug formulations. Science advances, 2020. 6: eabb6594.
3.	Gullapalli, R. P., Mazzitelli, C. L. Polyethylene glycols in oral and parenteral formulations—A critical review. International Journal of Pharmaceutics, 2015. 496(2): 219-239.
4.	Yousif, M. Y., et al.. Deriving a blood-mimicking fluid for particle image velocimetry in Sylgard-184 vascular models. In Annual International Conference of the IEEE Engineering in Medicine and Biology Society, 2009 (pp. 1412-1415
5.	Watt, R. P., et al. (2019). Injectability as a function of viscosity and dosing materials for subcutaneous administration. International Journal of Pharmaceutics, 2019:554, 376-386.
ACKNOWLEDGMENT
This research was funded by the MESDT, Republic of Serbia through Grant Agreement with University of Belgrade-Faculty of Pharmacy No: 451-03-68/2022-14/200161 and supported by the Science Fund of the Republic of Serbia, GRANT No 7749108, Neuroimmune aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA and/or sigma-2 receptors: In vitro/in vivo delineation by nano- and hiPSC-based platform - NanoCellEmоCog.",
journal = "9th BBBB International conference on pharmaceutical sciences; 15th - 17th September, Ljubljana, Slovenia",
title = "A proposal of innovative injectability assessment method for intravenous formulations - case study on PEGylated nanoemulsions",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4269"
}
Đoković, J., Savić, S., Cekić, N.,& Savić, S.. (2022). A proposal of innovative injectability assessment method for intravenous formulations - case study on PEGylated nanoemulsions. in 9th BBBB International conference on pharmaceutical sciences; 15th - 17th September, Ljubljana, Slovenia.
https://hdl.handle.net/21.15107/rcub_farfar_4269
Đoković J, Savić S, Cekić N, Savić S. A proposal of innovative injectability assessment method for intravenous formulations - case study on PEGylated nanoemulsions. in 9th BBBB International conference on pharmaceutical sciences; 15th - 17th September, Ljubljana, Slovenia. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4269 .
Đoković, Jelena, Savić, Sanela, Cekić, Nebojša, Savić, Snežana, "A proposal of innovative injectability assessment method for intravenous formulations - case study on PEGylated nanoemulsions" in 9th BBBB International conference on pharmaceutical sciences; 15th - 17th September, Ljubljana, Slovenia (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4269 .

Analyzing the impact of the oil phase selection and curcumin presence on the nanoemulsion stabilizing layer using electron paramagnetic resonance spectroscopy

Đoković, Jelena; Demisli, Sotiria; Papadimitriou, Vassiliki; Xenakis, Aristotelis; Savić, Snežana

(2022)

TY  - CONF
AU  - Đoković, Jelena
AU  - Demisli, Sotiria
AU  - Papadimitriou, Vassiliki
AU  - Xenakis, Aristotelis
AU  - Savić, Snežana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4284
AB  - ANALYZING THE IMPACT OF THE OIL PHASE SELECTION AND CURCUMIN
PRESENCE ON THE NANOEMULSION STABILIZING LAYER USING ELECTRON
PARAMAGNETIC RESONANCE SPECTROSCOPY
Jelena	Đoković1*, Sotiria Demisli2, Vassiliki Papadimitriou2,		
Aristotelis Xenakis2, Snežana Savić1
1University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical
Technology and Cosmetology, Belgrade, Serbia
2National Hellenic Research Foundation – Institute of Chemical Biology, Athens,
Greece
*jelenadj@pharmacy.bg.ac.rs
The stabilizing layer of nanoemulsions impacts their stability and destiny upon in vivo
administration (1). The aim of this work was to gain information about the dynamics of the
surfactants’ monolayer when different oils (soybean / fish) were used, and obtain data
regarding the localization of curcumin (2), an active compound with many potential health
benefits, using electron paramagnetic resonance (EPR) spectroscopy. Formulations were
analysed using EPR technique with three different spin probes: 5-, 12- and 16-doxyl stearic
acid (DSA), to investigate membrane dynamics at different depths. The results indicated that
the oil type played a crucial role, not only on the structure, but also in the localization of the
bioactive compound. The addition of curcumin changed the rotational correlation time (τR)
values, most notably for 5-DSA, both in soybean oil and fish oil nanoemulsions, indicating its
localization in the stabilizing layer, but with opposite effects. In the soybean oil
nanoemulsion the addition of curcumin increased spin probe mobility, with τR decreasing
from 2.18±0.60 ns to 1.66±0.61 ns, indicating a less rigid stabilizing structure, while in the
fish oil formulations it resulted in a more rigid structure reflected in τR increase from
1.19±0.10 ns to 2.96±0.81 ns and 1.63±0.13 ns to 2.27±0.19 ns, for 5-DSA and 12-DSA,
respectively. This study concluded that the curcumin is located in the stabilizing layer of
nanoemulsions, but its impact on stabilizing layer structure depended on the oil phase
selection, with particular stabilizing effects on fish oil nanoemulsions.
References
1. Nikolic, I. et al. Curcumin-loaded low‐energy nanoemulsions: Linking EPR spectroscopy‐
analysed microstructure and antioxidant potential with in vitro evaluated biological activity.
J. Mol. Liq. 2020, 301, 112479.
2. Griffith, O.H. and Jost, P.C. Lipid Spin Labels in Biological Membrane. In Spin Labeling,
Theory and Applications; Berliner, L.J., Eds.; Academic Press: New York, NY, USA, 1976;
pp 454–484
Acknowledgements
This research was funded by the MESDT, Republic of Serbia through Grant Agreement
with University of Belgrade – Faculty of Pharmacy No: 451-03-68/2022-14/200161 and
supported by the Science Fund of the Republic of Serbia, GRANT No 7749108, Neuroimmune
aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA
and/or sigma‐2 receptors: In vitro/in vivo delineation by nano‐	 and hiPSC‐based platform -
NanoCellEmоCog
C3  - 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija
T1  - Analyzing the impact of the oil phase selection and curcumin presence on the nanoemulsion stabilizing layer using electron paramagnetic resonance spectroscopy
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4284
ER  - 
@conference{
author = "Đoković, Jelena and Demisli, Sotiria and Papadimitriou, Vassiliki and Xenakis, Aristotelis and Savić, Snežana",
year = "2022",
abstract = "ANALYZING THE IMPACT OF THE OIL PHASE SELECTION AND CURCUMIN
PRESENCE ON THE NANOEMULSION STABILIZING LAYER USING ELECTRON
PARAMAGNETIC RESONANCE SPECTROSCOPY
Jelena	Đoković1*, Sotiria Demisli2, Vassiliki Papadimitriou2,		
Aristotelis Xenakis2, Snežana Savić1
1University of Belgrade – Faculty of Pharmacy, Department of Pharmaceutical
Technology and Cosmetology, Belgrade, Serbia
2National Hellenic Research Foundation – Institute of Chemical Biology, Athens,
Greece
*jelenadj@pharmacy.bg.ac.rs
The stabilizing layer of nanoemulsions impacts their stability and destiny upon in vivo
administration (1). The aim of this work was to gain information about the dynamics of the
surfactants’ monolayer when different oils (soybean / fish) were used, and obtain data
regarding the localization of curcumin (2), an active compound with many potential health
benefits, using electron paramagnetic resonance (EPR) spectroscopy. Formulations were
analysed using EPR technique with three different spin probes: 5-, 12- and 16-doxyl stearic
acid (DSA), to investigate membrane dynamics at different depths. The results indicated that
the oil type played a crucial role, not only on the structure, but also in the localization of the
bioactive compound. The addition of curcumin changed the rotational correlation time (τR)
values, most notably for 5-DSA, both in soybean oil and fish oil nanoemulsions, indicating its
localization in the stabilizing layer, but with opposite effects. In the soybean oil
nanoemulsion the addition of curcumin increased spin probe mobility, with τR decreasing
from 2.18±0.60 ns to 1.66±0.61 ns, indicating a less rigid stabilizing structure, while in the
fish oil formulations it resulted in a more rigid structure reflected in τR increase from
1.19±0.10 ns to 2.96±0.81 ns and 1.63±0.13 ns to 2.27±0.19 ns, for 5-DSA and 12-DSA,
respectively. This study concluded that the curcumin is located in the stabilizing layer of
nanoemulsions, but its impact on stabilizing layer structure depended on the oil phase
selection, with particular stabilizing effects on fish oil nanoemulsions.
References
1. Nikolic, I. et al. Curcumin-loaded low‐energy nanoemulsions: Linking EPR spectroscopy‐
analysed microstructure and antioxidant potential with in vitro evaluated biological activity.
J. Mol. Liq. 2020, 301, 112479.
2. Griffith, O.H. and Jost, P.C. Lipid Spin Labels in Biological Membrane. In Spin Labeling,
Theory and Applications; Berliner, L.J., Eds.; Academic Press: New York, NY, USA, 1976;
pp 454–484
Acknowledgements
This research was funded by the MESDT, Republic of Serbia through Grant Agreement
with University of Belgrade – Faculty of Pharmacy No: 451-03-68/2022-14/200161 and
supported by the Science Fund of the Republic of Serbia, GRANT No 7749108, Neuroimmune
aspects of mood, anxiety and cognitive effects of leads/drug candidates acting at GABAA
and/or sigma‐2 receptors: In vitro/in vivo delineation by nano‐	 and hiPSC‐based platform -
NanoCellEmоCog",
journal = "8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija",
title = "Analyzing the impact of the oil phase selection and curcumin presence on the nanoemulsion stabilizing layer using electron paramagnetic resonance spectroscopy",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4284"
}
Đoković, J., Demisli, S., Papadimitriou, V., Xenakis, A.,& Savić, S.. (2022). Analyzing the impact of the oil phase selection and curcumin presence on the nanoemulsion stabilizing layer using electron paramagnetic resonance spectroscopy. in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija.
https://hdl.handle.net/21.15107/rcub_farfar_4284
Đoković J, Demisli S, Papadimitriou V, Xenakis A, Savić S. Analyzing the impact of the oil phase selection and curcumin presence on the nanoemulsion stabilizing layer using electron paramagnetic resonance spectroscopy. in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija. 2022;.
https://hdl.handle.net/21.15107/rcub_farfar_4284 .
Đoković, Jelena, Demisli, Sotiria, Papadimitriou, Vassiliki, Xenakis, Aristotelis, Savić, Snežana, "Analyzing the impact of the oil phase selection and curcumin presence on the nanoemulsion stabilizing layer using electron paramagnetic resonance spectroscopy" in 8. Kongres farmaceuta Srbije; 12.-15. oktobar, Beograd, Srbija (2022),
https://hdl.handle.net/21.15107/rcub_farfar_4284 .

The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions

Đoković, Jelena; Demisli, Sotiria; Savić, Sanela; Marković, Bojan; Cekić, Nebojša D.; Ranđelović, Danijela V.; Mitrović, Jelena; Lunter, Dominique Jasmin; Papadimitriou, Vassiliki; Xenakis, Aristotelis; Savić, Snežana

(MDPI, 2022)

TY  - JOUR
AU  - Đoković, Jelena
AU  - Demisli, Sotiria
AU  - Savić, Sanela
AU  - Marković, Bojan
AU  - Cekić, Nebojša D.
AU  - Ranđelović, Danijela V.
AU  - Mitrović, Jelena
AU  - Lunter, Dominique Jasmin
AU  - Papadimitriou, Vassiliki
AU  - Xenakis, Aristotelis
AU  - Savić, Snežana
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4265
AB  - A nanotechnology-based approach to drug delivery presents one of the biggest trends in biomedical science that can provide increased active concentration, bioavailability, and safety compared to conventional drug-delivery systems. Nanoemulsions stand out amongst other nanocarriers for being biodegradable, biocompatible, and relatively easy to manufacture. For improved drug-delivery properties, longer circulation for the nanoemulsion droplets should be provided, to allow the active to reach the target site. One of the strategies used for this purpose is PEGylation. The aim of this research was assessing the impact of the oil phase selection, soybean or fish oil mixtures with medium chain triglycerides, on the physicochemical characteristics and injectability of curcumin-loaded PEGylated nanoemulsions. Electron paramagnetic resonance spectroscopy demonstrated the structural impact of the oil phase on the stabilizing layer of nanoemulsions, with a more pronounced stabilizing effect of curcumin observed in the fish oil nanoemulsion compared to the soybean oil one. The design of the experiment study, employed to simultaneously assess the impact of the oil phase, different PEGylated phospholipids and their concentrations, as well as the presence of curcumin, showed that not only the investigated factors alone, but also their interactions, had a significant influence on the critical quality attributes of the PEGylated nanoemulsions. Detailed physicochemical characterization of the NEs found all formulations were appropriate for parenteral administration and remained stable during two years of storage, with the preserved antioxidant activity demonstrated by DPPH and FRAP assays. In vitro release studies showed a more pronounced release of curcumin from the fish oil NEs compared to that from the soybean oil ones. The innovative in vitro injectability assessment, designed to mimic intravenous application, proved that all formulations tested in selected experimental setting could be employed in prospective in vivo studies. Overall, the current study shows the importance of oil phase selection when formulating PEGylated nanoemulsions
PB  - MDPI
T2  - Pharmaceutics
T1  - The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions
VL  - 14
IS  - 8
DO  - 10.3390/pharmaceutics14081666
ER  - 
@article{
author = "Đoković, Jelena and Demisli, Sotiria and Savić, Sanela and Marković, Bojan and Cekić, Nebojša D. and Ranđelović, Danijela V. and Mitrović, Jelena and Lunter, Dominique Jasmin and Papadimitriou, Vassiliki and Xenakis, Aristotelis and Savić, Snežana",
year = "2022",
abstract = "A nanotechnology-based approach to drug delivery presents one of the biggest trends in biomedical science that can provide increased active concentration, bioavailability, and safety compared to conventional drug-delivery systems. Nanoemulsions stand out amongst other nanocarriers for being biodegradable, biocompatible, and relatively easy to manufacture. For improved drug-delivery properties, longer circulation for the nanoemulsion droplets should be provided, to allow the active to reach the target site. One of the strategies used for this purpose is PEGylation. The aim of this research was assessing the impact of the oil phase selection, soybean or fish oil mixtures with medium chain triglycerides, on the physicochemical characteristics and injectability of curcumin-loaded PEGylated nanoemulsions. Electron paramagnetic resonance spectroscopy demonstrated the structural impact of the oil phase on the stabilizing layer of nanoemulsions, with a more pronounced stabilizing effect of curcumin observed in the fish oil nanoemulsion compared to the soybean oil one. The design of the experiment study, employed to simultaneously assess the impact of the oil phase, different PEGylated phospholipids and their concentrations, as well as the presence of curcumin, showed that not only the investigated factors alone, but also their interactions, had a significant influence on the critical quality attributes of the PEGylated nanoemulsions. Detailed physicochemical characterization of the NEs found all formulations were appropriate for parenteral administration and remained stable during two years of storage, with the preserved antioxidant activity demonstrated by DPPH and FRAP assays. In vitro release studies showed a more pronounced release of curcumin from the fish oil NEs compared to that from the soybean oil ones. The innovative in vitro injectability assessment, designed to mimic intravenous application, proved that all formulations tested in selected experimental setting could be employed in prospective in vivo studies. Overall, the current study shows the importance of oil phase selection when formulating PEGylated nanoemulsions",
publisher = "MDPI",
journal = "Pharmaceutics",
title = "The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions",
volume = "14",
number = "8",
doi = "10.3390/pharmaceutics14081666"
}
Đoković, J., Demisli, S., Savić, S., Marković, B., Cekić, N. D., Ranđelović, D. V., Mitrović, J., Lunter, D. J., Papadimitriou, V., Xenakis, A.,& Savić, S.. (2022). The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions. in Pharmaceutics
MDPI., 14(8).
https://doi.org/10.3390/pharmaceutics14081666
Đoković J, Demisli S, Savić S, Marković B, Cekić ND, Ranđelović DV, Mitrović J, Lunter DJ, Papadimitriou V, Xenakis A, Savić S. The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions. in Pharmaceutics. 2022;14(8).
doi:10.3390/pharmaceutics14081666 .
Đoković, Jelena, Demisli, Sotiria, Savić, Sanela, Marković, Bojan, Cekić, Nebojša D., Ranđelović, Danijela V., Mitrović, Jelena, Lunter, Dominique Jasmin, Papadimitriou, Vassiliki, Xenakis, Aristotelis, Savić, Snežana, "The Impact of the Oil Phase Selection on Physicochemical Properties, Long-Term Stability, In Vitro Performance and Injectability of Curcumin-Loaded PEGylated Nanoemulsions" in Pharmaceutics, 14, no. 8 (2022),
https://doi.org/10.3390/pharmaceutics14081666 . .
2
2

Overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: A knowledge-based approach

Mitrović, Jelena; Divović-Matović, Branka; Knutson, Daniel; Đoković, Jelena; Kremenović, Aleksandar; Dobričić, Vladimir; Ranđelović, Danijela; Pantelić, Ivana; Cook, James; Savić, Miroslav; Savić, Snežana

(MDPI AG, 2021)

TY  - JOUR
AU  - Mitrović, Jelena
AU  - Divović-Matović, Branka
AU  - Knutson, Daniel
AU  - Đoković, Jelena
AU  - Kremenović, Aleksandar
AU  - Dobričić, Vladimir
AU  - Ranđelović, Danijela
AU  - Pantelić, Ivana
AU  - Cook, James
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3934
AB  - Poor water solubility of new chemical entities is considered as one of the main obstacles in drug development, as it usually leads to low bioavailability after administration. To overcome these problems, the selection of the appropriate formulation technology needs to be based on the physicochemical properties of the drug and introduced in the early stages of drug research. One example of the new potential drug substance with poor solubility is DK-I-60-3, deuterated pyrazoloquinolinone, designed for the treatment of various neuropsychiatric disorders. In this research, based on preformulation studies, nanocrystal technology was chosen to improve the oral bioavailability of DK-I-60-3. Nanocrystal dispersions stabilized by sodium lauryl sulfate and polyvinylpyrrolidone were prepared by modified wet media milling technique, with the selection of appropriate process and formulation parameters. The nanoparticles characterization included particle size and zeta potential measurements, differential scanning calorimetry, X-ray powder diffraction, dissolution and solubility study, and in vivo pharmacokinetic experiments. Developed formulations had small uniform particle sizes and were stable for three months. Nanonization caused decreased crystallite size and induced crystal defects formation, as well as a DK-I-60-3 solubility increase. Furthermore, after oral administration of the developed formulations in rats, two to three-fold bioavailability enhancement was observed in plasma and investigated organs, including the brain.
PB  - MDPI AG
T2  - Pharmaceutics
T1  - Overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: A knowledge-based approach
VL  - 13
IS  - 8
DO  - 10.3390/pharmaceutics13081188
ER  - 
@article{
author = "Mitrović, Jelena and Divović-Matović, Branka and Knutson, Daniel and Đoković, Jelena and Kremenović, Aleksandar and Dobričić, Vladimir and Ranđelović, Danijela and Pantelić, Ivana and Cook, James and Savić, Miroslav and Savić, Snežana",
year = "2021",
abstract = "Poor water solubility of new chemical entities is considered as one of the main obstacles in drug development, as it usually leads to low bioavailability after administration. To overcome these problems, the selection of the appropriate formulation technology needs to be based on the physicochemical properties of the drug and introduced in the early stages of drug research. One example of the new potential drug substance with poor solubility is DK-I-60-3, deuterated pyrazoloquinolinone, designed for the treatment of various neuropsychiatric disorders. In this research, based on preformulation studies, nanocrystal technology was chosen to improve the oral bioavailability of DK-I-60-3. Nanocrystal dispersions stabilized by sodium lauryl sulfate and polyvinylpyrrolidone were prepared by modified wet media milling technique, with the selection of appropriate process and formulation parameters. The nanoparticles characterization included particle size and zeta potential measurements, differential scanning calorimetry, X-ray powder diffraction, dissolution and solubility study, and in vivo pharmacokinetic experiments. Developed formulations had small uniform particle sizes and were stable for three months. Nanonization caused decreased crystallite size and induced crystal defects formation, as well as a DK-I-60-3 solubility increase. Furthermore, after oral administration of the developed formulations in rats, two to three-fold bioavailability enhancement was observed in plasma and investigated organs, including the brain.",
publisher = "MDPI AG",
journal = "Pharmaceutics",
title = "Overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: A knowledge-based approach",
volume = "13",
number = "8",
doi = "10.3390/pharmaceutics13081188"
}
Mitrović, J., Divović-Matović, B., Knutson, D., Đoković, J., Kremenović, A., Dobričić, V., Ranđelović, D., Pantelić, I., Cook, J., Savić, M.,& Savić, S.. (2021). Overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: A knowledge-based approach. in Pharmaceutics
MDPI AG., 13(8).
https://doi.org/10.3390/pharmaceutics13081188
Mitrović J, Divović-Matović B, Knutson D, Đoković J, Kremenović A, Dobričić V, Ranđelović D, Pantelić I, Cook J, Savić M, Savić S. Overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: A knowledge-based approach. in Pharmaceutics. 2021;13(8).
doi:10.3390/pharmaceutics13081188 .
Mitrović, Jelena, Divović-Matović, Branka, Knutson, Daniel, Đoković, Jelena, Kremenović, Aleksandar, Dobričić, Vladimir, Ranđelović, Danijela, Pantelić, Ivana, Cook, James, Savić, Miroslav, Savić, Snežana, "Overcoming the low oral bioavailability of deuterated pyrazoloquinolinone ligand dk-i-60-3 by nanonization: A knowledge-based approach" in Pharmaceutics, 13, no. 8 (2021),
https://doi.org/10.3390/pharmaceutics13081188 . .
7
8

Curcumin loaded pegylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot study on rats

Đoković, Jelena; Savić, Sanela; Mitrović, Jelena; Nikolić, Ines; Marković, Bojan; Ranđelović, Danijela; Antić-Stanković, Jelena; Božić, Dragana; Cekić, Nebojša; Stevanović, Vladimir; Batinić, Bojan; Aranđelović, Jovana; Savić, Miroslav; Savić, Snežana

(MDPI, 2021)

TY  - JOUR
AU  - Đoković, Jelena
AU  - Savić, Sanela
AU  - Mitrović, Jelena
AU  - Nikolić, Ines
AU  - Marković, Bojan
AU  - Ranđelović, Danijela
AU  - Antić-Stanković, Jelena
AU  - Božić, Dragana
AU  - Cekić, Nebojša
AU  - Stevanović, Vladimir
AU  - Batinić, Bojan
AU  - Aranđelović, Jovana
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2021
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5541
AB  - The current study describes the experimental design guided development of PEGylated nanoemulsions as parenteral delivery systems for curcumin, a powerful antioxidant, as well as the evaluation of their physicochemical characteristics and antioxidant activity during the two years of storage. Experimental design setup helped development of nanoemulsion templates with critical quality attributes in line with parenteral application route. Curcumin-loaded nanoemulsions showed mean droplet size about 105 nm, polydispersity index <0.15, zeta potential of −40 mV, and acceptable osmolality of about 550 mOsm/kg. After two years of storage at room temperature, all formulations remained stable. Moreover, antioxidant activity remained intact, as demonstrated by DPPH (IC50 values 0.078–0.075 mg/mL after two years) and FRAPS assays. In vitro release testing proved that PEGylated phospholipids slowed down the curcumin release from nanoemulsions. The nanoemulsion carrier has been proven safe by the MTT test conducted with MRC-5 cell line, and effective on LS cell line. Results from the pharmacokinetic pilot study implied the PEGylated nanoemulsions improved plasma residence of curcumin 20 min after intravenous administration, compared to the non-PEGylated nanoemulsion (two-fold higher) or curcumin solution (three-fold higher). Overall, conclusion suggests that developed PEGylated nanoemulsions present an acceptable delivery system for parenteral administration of curcumin, being effective in preserving its stability and antioxidant capacity at the level highly comparable to the initial findings.
PB  - MDPI
T2  - International Journal of Molecular Sciences
T1  - Curcumin loaded pegylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot study on rats
VL  - 22
IS  - 15
DO  - 10.3390/ijms22157991
ER  - 
@article{
author = "Đoković, Jelena and Savić, Sanela and Mitrović, Jelena and Nikolić, Ines and Marković, Bojan and Ranđelović, Danijela and Antić-Stanković, Jelena and Božić, Dragana and Cekić, Nebojša and Stevanović, Vladimir and Batinić, Bojan and Aranđelović, Jovana and Savić, Miroslav and Savić, Snežana",
year = "2021",
abstract = "The current study describes the experimental design guided development of PEGylated nanoemulsions as parenteral delivery systems for curcumin, a powerful antioxidant, as well as the evaluation of their physicochemical characteristics and antioxidant activity during the two years of storage. Experimental design setup helped development of nanoemulsion templates with critical quality attributes in line with parenteral application route. Curcumin-loaded nanoemulsions showed mean droplet size about 105 nm, polydispersity index <0.15, zeta potential of −40 mV, and acceptable osmolality of about 550 mOsm/kg. After two years of storage at room temperature, all formulations remained stable. Moreover, antioxidant activity remained intact, as demonstrated by DPPH (IC50 values 0.078–0.075 mg/mL after two years) and FRAPS assays. In vitro release testing proved that PEGylated phospholipids slowed down the curcumin release from nanoemulsions. The nanoemulsion carrier has been proven safe by the MTT test conducted with MRC-5 cell line, and effective on LS cell line. Results from the pharmacokinetic pilot study implied the PEGylated nanoemulsions improved plasma residence of curcumin 20 min after intravenous administration, compared to the non-PEGylated nanoemulsion (two-fold higher) or curcumin solution (three-fold higher). Overall, conclusion suggests that developed PEGylated nanoemulsions present an acceptable delivery system for parenteral administration of curcumin, being effective in preserving its stability and antioxidant capacity at the level highly comparable to the initial findings.",
publisher = "MDPI",
journal = "International Journal of Molecular Sciences",
title = "Curcumin loaded pegylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot study on rats",
volume = "22",
number = "15",
doi = "10.3390/ijms22157991"
}
Đoković, J., Savić, S., Mitrović, J., Nikolić, I., Marković, B., Ranđelović, D., Antić-Stanković, J., Božić, D., Cekić, N., Stevanović, V., Batinić, B., Aranđelović, J., Savić, M.,& Savić, S.. (2021). Curcumin loaded pegylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot study on rats. in International Journal of Molecular Sciences
MDPI., 22(15).
https://doi.org/10.3390/ijms22157991
Đoković J, Savić S, Mitrović J, Nikolić I, Marković B, Ranđelović D, Antić-Stanković J, Božić D, Cekić N, Stevanović V, Batinić B, Aranđelović J, Savić M, Savić S. Curcumin loaded pegylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot study on rats. in International Journal of Molecular Sciences. 2021;22(15).
doi:10.3390/ijms22157991 .
Đoković, Jelena, Savić, Sanela, Mitrović, Jelena, Nikolić, Ines, Marković, Bojan, Ranđelović, Danijela, Antić-Stanković, Jelena, Božić, Dragana, Cekić, Nebojša, Stevanović, Vladimir, Batinić, Bojan, Aranđelović, Jovana, Savić, Miroslav, Savić, Snežana, "Curcumin loaded pegylated nanoemulsions designed for maintained antioxidant effects and improved bioavailability: A pilot study on rats" in International Journal of Molecular Sciences, 22, no. 15 (2021),
https://doi.org/10.3390/ijms22157991 . .
16
15

Nanosuspensions of novel deuterated pyrazoloquinolinones ligand (DK-I-56-1): lyophilization procedure development through cryoprotectant selection and stability study

Mitrović, Jelena; Bjelošević, Maja; Đoković, Jelena; Ahlin Grabnar, Pegi; Planinšek, Odon; Knutson, Daniel; Cook, James; Savić, Miroslav; Savić, Snežana

(2020)

TY  - CONF
AU  - Mitrović, Jelena
AU  - Bjelošević, Maja
AU  - Đoković, Jelena
AU  - Ahlin Grabnar, Pegi
AU  - Planinšek, Odon
AU  - Knutson, Daniel
AU  - Cook, James
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3744
AB  - Despite of good pharmacodynamics of DK-I-56-1, novel deuterated pyrazoloquinolinones ligand, low solubility limits its administration. Nanosuspensions can help to overcome this problem, but its small particle size usually leads to particle agglomeration in short period of time. This phenomenon can be prevented by performing lyophilization. In this study cryoprotectants selection as well as characterization (particle size measurements after redispersion, scanning electron microscopy, differential scanning calorimetry and thermogravimetric measurements) of obtained freeze dried preparations was carried out. It was observed that sucrose/mannitol ratio 1:1 and 3:2 in total concentration of 10% can preserve particle size during lyophilization. However, after stability study conducted during one month storage at 25 °C and 40 °C, particle size remained in submicron range only in one sample. Changes in particle size were also followed by changes in polymorphic form of mannitol. It can be concluded that changes of crystal forms in freeze dried preparations during storage could jeopardize their stability, and therefore should be carefully examined.
T1  - Nanosuspensions of novel deuterated pyrazoloquinolinones ligand (DK-I-56-1): lyophilization procedure development through cryoprotectant selection and stability study
UR  - https://hdl.handle.net/21.15107/rcub_farfar_3744
ER  - 
@conference{
author = "Mitrović, Jelena and Bjelošević, Maja and Đoković, Jelena and Ahlin Grabnar, Pegi and Planinšek, Odon and Knutson, Daniel and Cook, James and Savić, Miroslav and Savić, Snežana",
year = "2020",
abstract = "Despite of good pharmacodynamics of DK-I-56-1, novel deuterated pyrazoloquinolinones ligand, low solubility limits its administration. Nanosuspensions can help to overcome this problem, but its small particle size usually leads to particle agglomeration in short period of time. This phenomenon can be prevented by performing lyophilization. In this study cryoprotectants selection as well as characterization (particle size measurements after redispersion, scanning electron microscopy, differential scanning calorimetry and thermogravimetric measurements) of obtained freeze dried preparations was carried out. It was observed that sucrose/mannitol ratio 1:1 and 3:2 in total concentration of 10% can preserve particle size during lyophilization. However, after stability study conducted during one month storage at 25 °C and 40 °C, particle size remained in submicron range only in one sample. Changes in particle size were also followed by changes in polymorphic form of mannitol. It can be concluded that changes of crystal forms in freeze dried preparations during storage could jeopardize their stability, and therefore should be carefully examined.",
title = "Nanosuspensions of novel deuterated pyrazoloquinolinones ligand (DK-I-56-1): lyophilization procedure development through cryoprotectant selection and stability study",
url = "https://hdl.handle.net/21.15107/rcub_farfar_3744"
}
Mitrović, J., Bjelošević, M., Đoković, J., Ahlin Grabnar, P., Planinšek, O., Knutson, D., Cook, J., Savić, M.,& Savić, S.. (2020). Nanosuspensions of novel deuterated pyrazoloquinolinones ligand (DK-I-56-1): lyophilization procedure development through cryoprotectant selection and stability study. .
https://hdl.handle.net/21.15107/rcub_farfar_3744
Mitrović J, Bjelošević M, Đoković J, Ahlin Grabnar P, Planinšek O, Knutson D, Cook J, Savić M, Savić S. Nanosuspensions of novel deuterated pyrazoloquinolinones ligand (DK-I-56-1): lyophilization procedure development through cryoprotectant selection and stability study. 2020;.
https://hdl.handle.net/21.15107/rcub_farfar_3744 .
Mitrović, Jelena, Bjelošević, Maja, Đoković, Jelena, Ahlin Grabnar, Pegi, Planinšek, Odon, Knutson, Daniel, Cook, James, Savić, Miroslav, Savić, Snežana, "Nanosuspensions of novel deuterated pyrazoloquinolinones ligand (DK-I-56-1): lyophilization procedure development through cryoprotectant selection and stability study" (2020),
https://hdl.handle.net/21.15107/rcub_farfar_3744 .

Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance

Mitrović, Jelena; Divović, Branka; Knutson, Daniel E.; Đoković, Jelena; Vulić, Predrag; Ranđelović, Danijela; Dobričić, Vladimir; Čalija, Bojan; Cook, James M.; Savić, Miroslav; Savić, Snežana

(Elsevier B.V., 2020)

TY  - JOUR
AU  - Mitrović, Jelena
AU  - Divović, Branka
AU  - Knutson, Daniel E.
AU  - Đoković, Jelena
AU  - Vulić, Predrag
AU  - Ranđelović, Danijela
AU  - Dobričić, Vladimir
AU  - Čalija, Bojan
AU  - Cook, James M.
AU  - Savić, Miroslav
AU  - Savić, Snežana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3640
AB  - DK-I-56–1 (7‑methoxy‑2-(4‑methoxy‑d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one), a recently developed deuterated pyrazoloquinolinone, has been recognized as a lead candidate for treatment of various neuropsychiatric disorders. During preclinical investigation of poorly water-soluble compounds such as DK-I-56–1, the application of nanotechnology could be advantageous due to improved safety and possibly increased bioavailability of nanosized formulation. DK-I-56–1 nanosuspensions stabilized by polysorbate 80, alone or in combination with poloxamers 188 i.e. 407 or d-α-tocopheryl polyethylene glycol 1000 succinate, were prepared using a small-scale media milling device. With particle size 208.7–250.6 nm and polydispersity index <0.250, selected nanodiseprsions were stable for three weeks. Pharmacokinetic and biodistribution studies following intraperitoneal administration of three types of formulation in mice indicated high plasma DK-I-56–1 levels after solution (10,228.6 ± 1037.2 ngh/ml) and nanosuspension (6770.4 ± 770.7 ngh/ml) but not suspension administration (966.0 ± 58.1 ngh/ml). However, distribution of DK-I-56–1 after solution was heavily influenced by its composition, and brain availability of nanosuspension was superior to that of solution formulation. In spontaneous locomotor activity test, the expected hyperlocomotor effect was observed after nanosuspension administration, without compromising impact of the vehicle/excipients used. Therefore, nanonization of drug compound assembled with proper selection of stabilizers may seemingly contribute further thorough testing of DK-I-56–1 preclinical efficacy.
PB  - Elsevier B.V.
T2  - European Journal of Pharmaceutical Sciences
T1  - Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance
VL  - 152
DO  - 10.1016/j.ejps.2020.105432
ER  - 
@article{
author = "Mitrović, Jelena and Divović, Branka and Knutson, Daniel E. and Đoković, Jelena and Vulić, Predrag and Ranđelović, Danijela and Dobričić, Vladimir and Čalija, Bojan and Cook, James M. and Savić, Miroslav and Savić, Snežana",
year = "2020",
abstract = "DK-I-56–1 (7‑methoxy‑2-(4‑methoxy‑d3-phenyl)-2,5-dihydro-3H-pyrazolo[4,3-c]quinolin-3-one), a recently developed deuterated pyrazoloquinolinone, has been recognized as a lead candidate for treatment of various neuropsychiatric disorders. During preclinical investigation of poorly water-soluble compounds such as DK-I-56–1, the application of nanotechnology could be advantageous due to improved safety and possibly increased bioavailability of nanosized formulation. DK-I-56–1 nanosuspensions stabilized by polysorbate 80, alone or in combination with poloxamers 188 i.e. 407 or d-α-tocopheryl polyethylene glycol 1000 succinate, were prepared using a small-scale media milling device. With particle size 208.7–250.6 nm and polydispersity index <0.250, selected nanodiseprsions were stable for three weeks. Pharmacokinetic and biodistribution studies following intraperitoneal administration of three types of formulation in mice indicated high plasma DK-I-56–1 levels after solution (10,228.6 ± 1037.2 ngh/ml) and nanosuspension (6770.4 ± 770.7 ngh/ml) but not suspension administration (966.0 ± 58.1 ngh/ml). However, distribution of DK-I-56–1 after solution was heavily influenced by its composition, and brain availability of nanosuspension was superior to that of solution formulation. In spontaneous locomotor activity test, the expected hyperlocomotor effect was observed after nanosuspension administration, without compromising impact of the vehicle/excipients used. Therefore, nanonization of drug compound assembled with proper selection of stabilizers may seemingly contribute further thorough testing of DK-I-56–1 preclinical efficacy.",
publisher = "Elsevier B.V.",
journal = "European Journal of Pharmaceutical Sciences",
title = "Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance",
volume = "152",
doi = "10.1016/j.ejps.2020.105432"
}
Mitrović, J., Divović, B., Knutson, D. E., Đoković, J., Vulić, P., Ranđelović, D., Dobričić, V., Čalija, B., Cook, J. M., Savić, M.,& Savić, S.. (2020). Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance. in European Journal of Pharmaceutical Sciences
Elsevier B.V.., 152.
https://doi.org/10.1016/j.ejps.2020.105432
Mitrović J, Divović B, Knutson DE, Đoković J, Vulić P, Ranđelović D, Dobričić V, Čalija B, Cook JM, Savić M, Savić S. Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance. in European Journal of Pharmaceutical Sciences. 2020;152.
doi:10.1016/j.ejps.2020.105432 .
Mitrović, Jelena, Divović, Branka, Knutson, Daniel E., Đoković, Jelena, Vulić, Predrag, Ranđelović, Danijela, Dobričić, Vladimir, Čalija, Bojan, Cook, James M., Savić, Miroslav, Savić, Snežana, "Nanocrystal dispersion of DK-I-56–1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance" in European Journal of Pharmaceutical Sciences, 152 (2020),
https://doi.org/10.1016/j.ejps.2020.105432 . .
7
3
7

Low-energy nanoemulsions as carriers for red raspberry seed oil: Formulation approach based on Raman spectroscopy and textural analysis, physicochemical properties, stability and in vitro antioxidant/ biological activity

Gledović, Ana; Janošević-Ležaić, Aleksandra; Krstonošić, Veljko; Đoković, Jelena; Nikolić, Ines; Bajuk-Bogdanović, Danica; Antić-Stanković, Jelena; Ranđelović, Danijela; Savić, Sanela M.; Filipović, Mila; Tamburić, Slobodanka; Savić, Snežana

(Public Library of Science, 2020)

TY  - JOUR
AU  - Gledović, Ana
AU  - Janošević-Ležaić, Aleksandra
AU  - Krstonošić, Veljko
AU  - Đoković, Jelena
AU  - Nikolić, Ines
AU  - Bajuk-Bogdanović, Danica
AU  - Antić-Stanković, Jelena
AU  - Ranđelović, Danijela
AU  - Savić, Sanela M.
AU  - Filipović, Mila
AU  - Tamburić, Slobodanka
AU  - Savić, Snežana
PY  - 2020
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3581
AB  - Considering a growing demand for medicinal/cosmetic products with natural actives, this study focuses on the low-energy nanoemulsions (LE-NEs) prepared via the Phase inversion composition (PIC) method at room temperature as potential carriers for natural oil. Four different red raspberry seed oils (ROs) were tested, as follows: cold-pressed vs. CO2- extracted, organic vs. non-organic, refined vs. unrefined. The oil phase was optimized with Tocopheryl acetate and Isostearyl isostearate, while water phase was adjusted with either glycerol or an antioxidant hydro-glycolic extract. This study has used a combined approach to formulation development, employing both conventional methods (pseudo-ternary phase diagram - PTPD, electrical conductivity, particle size measurements, microscopical analysis, and rheological measurements) and the methods novel to this area, such as textural analysis and Raman spectroscopy. Raman spectroscopy has detected fine differences in chemical composition among ROs, and it detected the interactions within nanoemulsions. It was shown that the cold-pressed, unrefined, organic grade oil (RO2) with 6.62% saturated fatty acids and 92.25% unsaturated fatty acids, was optimal for the LE-NEs. Textural analysis confirmed the existence of cubic gel-like phase as a crucial step in the formation of stable RO2-loaded LE-NEs, with droplets in the narrow nano-range (125 to 135 nm; PDI ≤ 0.1). The DPPH test in methanol and ABTS in aqueous medium have revealed a synergistic free radical scavenging effect between lipophilic and hydrophilic antioxidants in LE-NEs. The nanoemulsion carrier has improved the biological effect of raw materials on HeLa cervical adenocarcinoma cells, while exhibiting good safety profile, as confirmed on MRC-5 normal human lung fibroblasts. Overall, this study has shown that low-energy nanoemulsions present very promising carriers for topical delivery of natural bioactives. Raman spectroscopy and textural analysis have proven to be a useful addition to the arsenal of methods used in the formulation and characterization of nanoemulsion systems.
PB  - Public Library of Science
T2  - PLoS ONE
T1  - Low-energy nanoemulsions as carriers for red raspberry seed oil: Formulation approach based on Raman spectroscopy and textural analysis, physicochemical properties, stability and in vitro antioxidant/ biological activity
VL  - 15
IS  - 4
DO  - 10.1371/journal.pone.0230993
ER  - 
@article{
author = "Gledović, Ana and Janošević-Ležaić, Aleksandra and Krstonošić, Veljko and Đoković, Jelena and Nikolić, Ines and Bajuk-Bogdanović, Danica and Antić-Stanković, Jelena and Ranđelović, Danijela and Savić, Sanela M. and Filipović, Mila and Tamburić, Slobodanka and Savić, Snežana",
year = "2020",
abstract = "Considering a growing demand for medicinal/cosmetic products with natural actives, this study focuses on the low-energy nanoemulsions (LE-NEs) prepared via the Phase inversion composition (PIC) method at room temperature as potential carriers for natural oil. Four different red raspberry seed oils (ROs) were tested, as follows: cold-pressed vs. CO2- extracted, organic vs. non-organic, refined vs. unrefined. The oil phase was optimized with Tocopheryl acetate and Isostearyl isostearate, while water phase was adjusted with either glycerol or an antioxidant hydro-glycolic extract. This study has used a combined approach to formulation development, employing both conventional methods (pseudo-ternary phase diagram - PTPD, electrical conductivity, particle size measurements, microscopical analysis, and rheological measurements) and the methods novel to this area, such as textural analysis and Raman spectroscopy. Raman spectroscopy has detected fine differences in chemical composition among ROs, and it detected the interactions within nanoemulsions. It was shown that the cold-pressed, unrefined, organic grade oil (RO2) with 6.62% saturated fatty acids and 92.25% unsaturated fatty acids, was optimal for the LE-NEs. Textural analysis confirmed the existence of cubic gel-like phase as a crucial step in the formation of stable RO2-loaded LE-NEs, with droplets in the narrow nano-range (125 to 135 nm; PDI ≤ 0.1). The DPPH test in methanol and ABTS in aqueous medium have revealed a synergistic free radical scavenging effect between lipophilic and hydrophilic antioxidants in LE-NEs. The nanoemulsion carrier has improved the biological effect of raw materials on HeLa cervical adenocarcinoma cells, while exhibiting good safety profile, as confirmed on MRC-5 normal human lung fibroblasts. Overall, this study has shown that low-energy nanoemulsions present very promising carriers for topical delivery of natural bioactives. Raman spectroscopy and textural analysis have proven to be a useful addition to the arsenal of methods used in the formulation and characterization of nanoemulsion systems.",
publisher = "Public Library of Science",
journal = "PLoS ONE",
title = "Low-energy nanoemulsions as carriers for red raspberry seed oil: Formulation approach based on Raman spectroscopy and textural analysis, physicochemical properties, stability and in vitro antioxidant/ biological activity",
volume = "15",
number = "4",
doi = "10.1371/journal.pone.0230993"
}
Gledović, A., Janošević-Ležaić, A., Krstonošić, V., Đoković, J., Nikolić, I., Bajuk-Bogdanović, D., Antić-Stanković, J., Ranđelović, D., Savić, S. M., Filipović, M., Tamburić, S.,& Savić, S.. (2020). Low-energy nanoemulsions as carriers for red raspberry seed oil: Formulation approach based on Raman spectroscopy and textural analysis, physicochemical properties, stability and in vitro antioxidant/ biological activity. in PLoS ONE
Public Library of Science., 15(4).
https://doi.org/10.1371/journal.pone.0230993
Gledović A, Janošević-Ležaić A, Krstonošić V, Đoković J, Nikolić I, Bajuk-Bogdanović D, Antić-Stanković J, Ranđelović D, Savić SM, Filipović M, Tamburić S, Savić S. Low-energy nanoemulsions as carriers for red raspberry seed oil: Formulation approach based on Raman spectroscopy and textural analysis, physicochemical properties, stability and in vitro antioxidant/ biological activity. in PLoS ONE. 2020;15(4).
doi:10.1371/journal.pone.0230993 .
Gledović, Ana, Janošević-Ležaić, Aleksandra, Krstonošić, Veljko, Đoković, Jelena, Nikolić, Ines, Bajuk-Bogdanović, Danica, Antić-Stanković, Jelena, Ranđelović, Danijela, Savić, Sanela M., Filipović, Mila, Tamburić, Slobodanka, Savić, Snežana, "Low-energy nanoemulsions as carriers for red raspberry seed oil: Formulation approach based on Raman spectroscopy and textural analysis, physicochemical properties, stability and in vitro antioxidant/ biological activity" in PLoS ONE, 15, no. 4 (2020),
https://doi.org/10.1371/journal.pone.0230993 . .
1
21
6
20